As physicians we prescribe a medication with the understanding that decision reflects the accumulated weight of scientific evidence. But what happens when science itself becomes the business. Who are we left to trust then?

Who Funds the Evidence

The entity with the greatest financial interest in the outcome of clinical research is also its primary funder.

Let that fact sink in for a moment.

Between 2006 and 2014, the number of NIH-funded clinical trials registered at ClinicalTrials.gov fell 24 percent, from 1,376 to 1,048, while industry-funded trials grew 43 percent, from 4,585 to 6,550 (Ehrhardt et al., JAMA, 2015). The NIH budget fell 14 percent in real terms over the same period, which explains part of the decline.

How Outcomes Get Shaped Without Falsifying Data

Industry-funded trials produce more favorable outcomes for sponsored products than independently funded research. It has been replicated across multiple independent reviews over two decades and published in the highest-tier medical literature (Bekelman et al., JAMA, 2003; Lexchin et al., BMJ, 2003; Lundh et al., Cochrane Database of Systematic Reviews, 2017).

Trial design can be manipulated to favor a sponsor’s product before a single patient is enrolled:

• Selecting patient populations where the drug performs best, choosing dosing regimens that favor the treatment arm, selecting a comparator at sub-therapeutic dose so the experimental drug appears superior.

• Composite endpoints combine a hard outcome like death with softer outcomes like hospitalization, inflating the apparent magnitude of benefit.

• Selective publication ensures that positive trials appear in the literature promptly while negative trials are delayed or never published, producing a body of evidence that systematically overstates benefit.

• Truncated follow-up ends a trial before long-term harms have time to accumulate.

• Subgroup mining searches through disaggregated data until a favorable result surfaces, then publishes that result as if it were the primary finding.

Technical accuracy and intellectual honesty are not the same thing, and a system engineered to produce misleading conclusions from accurate data is a dishonest system.

How Truthful Numbers Lie

The ASCOT-LLA trial, published in The Lancet in 2003, found that atorvastatin reduced the risk of heart attack by 36 percent in the studied population (Sever et al., Lancet, 2003). That figure, the relative risk reduction, was mathematically accurate and appeared in direct-to-consumer advertising.

What the advertising did not communicate was the absolute risk reduction: the heart attack rate fell from approximately 3.0 percent in the placebo group to 1.9 percent in the treatment group over the study period. The 36 percent relative risk reduction is simply the mathematical expression of that 1.1 percentage point absolute difference as a proportion of the 3.0 percent baseline risk.

Both numbers describe the same finding. They produce entirely different impressions of benefit in the mind of a patient or a physician who is not trained to recognize which one is being presented.

Atorvastatin has demonstrated genuine clinical benefit in appropriate patient populations, and nothing in this example should be taken as stating otherwise. This practice is not unique to this drug or this campaign. It was and remains a pervasive feature of pharmaceutical marketing and of how trial results are framed in publications and communicated to the clinical community.

Statistically Significant, But Clinically Significant?

It appears in pharmaceutical marketing, journal abstracts, prescribing guidelines, and conversations between physicians and patients. It carries the authority of clinical judgment implying that someone with medical training has evaluated and determined it matters.

A trial with enough participants can demonstrate statistical significance for an effect so small it changes nothing about how a patient feels or functions. The logical question becomes, is the effect clinically meaningful?: significant enough to matter in terms of how a patient feels, functions, survives, or dies. The final question is, do the benefit has clinical value?: whether the demonstrated effect is worth the cost or the risk, versus available alternatives.

The influenza antiviral oseltamivir (Tamiflu) is the clearest documented illustration of the gap between these three questions. The drug received FDA approval in 1999, promoted as reducing the severity and duration of influenza and preventing serious complications. Governments worldwide stockpiled it at a cost of billions of dollars during pandemic preparedness planning. The supporting evidence was largely manufacturer-funded, and the full underlying trial data was withheld from independent researchers for years.

When the Cochrane Collaboration obtained and analyzed the complete clinical study reports, the findings were precise (Jefferson et al., Cochrane Database of Systematic Reviews, 2014). Tamiflu reduced time to first alleviation of symptoms in otherwise healthy adults by 16.8 hours, from approximately seven days to 6.3 days. The independent also review found no good evidence to support reduction in hospitalizations, serious complications, or transmission.

Statistically significant, yes. Clinically meaningful or valuable, not in my opinion.

The Ghost-Writing Scandal

Merck created a systematic editorial process for its arthritis drug rofecoxib (Vioxx) in which company employees and contracted medical publishing companies wrote the manuscripts, determined the target journals, and arranged for the names of external academic investigators to appear as primary authors after the content was completed. Investigators received honoraria for lending their names to research they did not conduct and papers they did not write (Ross et al., JAMA, 2008).

This was documented through internal company materials released during litigation and subsequently published in JAMA. The drug was voluntarily withdrawn from the market in September 2004 after research demonstrated it doubled the risk of heart attack and stroke if taken for more than 18 months. It had been on the market for five years. Merck subsequently settled with plaintiffs for $4.85 billion.

On reviewing the JAMA documentation, the journal’s editor-in-chief, Catherine D. DeAngelis, stated: “The manipulation is disgusting. I just didn’t realize the extent.”. The Vioxx case don’t represent an isolated failure by a single company acting in an unusual way. The JAMA editorial accompanying the Ross findings noted explicitly that these practices were not uncommon, calling for immediate reform.

The FDA’s Structural Vulnerability

The FDA’s approval process requires the manufacturer to submit the clinical trial data supporting safety and efficacy. The agency evaluates that data but does not independently conduct or replicate the trials. The integrity of the process therefore depends entirely on the integrity of data submitted by the entity with the most direct financial interest in the approval.

Since its establishment in 1992, the accelerated approval pathway has allowed drugs onto the market based on surrogate endpoints, indirect biological measures assumed to predict clinical benefit, before actual clinical benefit has been demonstrated. Post-approval confirmatory trials are required to verify that benefit but in practice, nearly half (112 of 253) of the drugs authorized through this pathway had not been confirmed as clinically effective as of a 2021 BMJ investigation and only 16 had ever been withdrawn (Mahase, BMJ, 2021). Twenty-four of those unconfirmed drugs had been on the market for more than five years, some for more than two decades.

The Institute for Clinical and Economic Review reported in April 2021 that FDA’s reluctance to follow through on withdrawal when confirmatory trials were not completed meant that sponsors had little practical incentive to conduct them. Aduhelm — an Alzheimer’s drug approved at $56,000 per year despite internal FDA scientific objections, subsequently discontinued after confirmatory trials failed — is the most publicly visible recent illustration of what that failure costs. More than 30 oncology drug indications have been withdrawn in the past five years as the FDA recalibrates its standards.

Guideline Committees and Threshold Creep

Clinical practice guidelines are the mechanism by which research findings become prescribing behavior at scale. They tell physicians what to treat, when to begin, and with what. The committees that write them have historically included members with significant financial relationships with the pharmaceutical industry (Bekelman et al., JAMA, 2003; Angell, The Truth About the Drug Companies, 2004).

The documented pattern across cardiovascular medicine, lipid management, and diabetes care is consistent: treatment thresholds have been progressively lowered over time, more patients defined as requiring pharmacological intervention, and combination therapy established as standard of care with earlier initiation. Abramson and Wright documented concerns about this directional pattern specifically in lipid-lowering guidelines as far back as 2007, noting that the guidelines had moved ahead of the evidence base supporting them (Lancet, 2007).

What This Produces at the Bedside

The clinical endpoint of these intersecting forces is visible in the care of older patients across American medicine. Polypharmacy defined as five or more concurrent medications, is common and consequences well documented: increased adverse drug events, drug-drug interactions, falls, cognitive impairment, and hospitalizations (Masnoon et al., BMC Geriatrics, 2017; Hajjar et al., American Journal of Geriatric Pharmacotherapy, 2007).

I observed this repeatedly: elderly patients presenting with altered mentation, cognitive changes, confusion, behavioral disturbance, that on careful medication review proved to be the consequence of multiple centrally acting and psychoactive drugs prescribed by different providers, each subsequent prescription treating a symptom that was likely a side effect of from a prior one.

To add insult to injury, these patients stayed in the hospital, underwent a battery of additional tests despite the obvious cause, adding tens of thousand of dollars in unnecessary healthcare expenses.

A Reasonable Proposal and an Honest Assessment of Its Prospects

One simple structural reform could address this conflict: pharmaceutical companies seeking FDA approval should be required to contribute to a pooled, independently administered research fund from which grants are awarded to unaffiliated investigators who design and conduct the confirmatory trials the FDA requires. The company that developed the drug no longer has any control over the trial that evaluates it.

The reason of why it does not exist: the financial interests that would fund this arrangement are the same interests that fund the political process required to mandate it.

In Science We Still Trust… But…

My point here is not that medications in common use are not working or are unsafe. The point is we should all demand more transparency about conflict of interest in medical research and support independent research at a governmental level.

When a new prescription is proposed, three questions are worth asking:

• What is the absolute risk reduction this drug provides for someone with my specific profile, not just the relative risk reduction?

• What are the alternatives, including non-pharmacological ones?

• If I am already taking multiple medications, who is reviewing the complete list for interactions?

These are not adversarial questions. They are the questions a well-informed patient asks. Your physician will recognize them as exactly that.

Found this article useful? Share your thoughts. Join the conversation below.

Educational content on The Metabolic Archives is free, because medical information should be accessible to everyone. If you find value and want to support the work, a paid subscription is available and genuinely appreciated. Visit the About Page for additional information.

Subscribe now

© 2026 The Metabolic Archives. All rights reserved.

We will start with the quintessential metabolic condition: Type 2 Diabetes Mellitus.

Type 2 Diabetes Mellitus

Diagnosis of Type 2 Diabetes Mellitus (T2DM) marks the moment when the body can no longer keep up with progressive insulin resistance. Glucose levels finally rise above normal. However, insulin resistance is an evolving process present but undetected for years, we call it pre-diabetes.

Accepted diagnostic criteria for diabetes as of the date of this article are:

• Fasting Plasma Glucose (FPG) ≥126 mg/dL (7.0 mmol/L) after ≥8 hours of fasting

• 2-Hour Plasma Glucose (2hPG) during 75g OGTT ≥200 mg/dL (11.1 mmol/L)

• HbA1c ≥6.5% (48 mmol/mol)

• Random Plasma Glucose ≥200 mg/dL

The classic presenting symptoms include:

• Polyuria — excessive urination

• Polydipsia — excessive thirst

• Polyphagia — excessive appetite

• Unexplained weight loss

As of 2021, 537 million adults worldwide were living with diabetes, a figure projected to reach 783 million by 2045 (IDF Diabetes Atlas, 10th Edition, 2021). In the United States alone, approximately 96 million adults, about one in three, have pre-diabetes, and the majority are unaware of it (CDC National Diabetes Statistics Report, 2022).

Common complication of diabetes include: retinal damage leading to loss of vision, cardiovascular disease, stroke, erectile dysfunction, sensory and autonomic nerve damage, and several others. One complication deserving special attention: T2DM is the most common cause of non-traumatic lower extremity amputation in the USA.

Is important to realize that the inflammatory vascular damage responsible for most diabetic complications starts 5-10 years before a formal diagnosis, and progresses undetected during the pre-diabetic phase. Early diagnosis and aggressive lifestyle modification can stop and reverse disease progression.

Diabetes mellitus will be covered in detail on a separate series. The initial article is already published here.

Hyperlipidemia

When the liver becomes insulin resistant, it continues to overproduce very low-density lipoprotein (VLDL) particles while simultaneously impairing triglyceride clearance. Cholesteryl ester transfer protein activity depletes high-density lipoprotein (HDL) in exchange for triglycerides, and hepatic lipase remodels the remaining low-density lipoprotein (LDL) particles into the small, dense subtype that penetrates the arterial wall more readily and persists longer in circulation.

The result is the atherogenic dyslipidemic triad: elevated triglycerides, reduced HDL, and small dense LDL predominance, a pattern linked to hepatic insulin resistance and substantially more atherogenic than elevated LDL cholesterol alone (Taskinen and Borén, Atherosclerosis, 2015).

While standard lipid panels report total LDL cholesterol, they do not distinguish large buoyant LDL from small dense LDL. A patient with insulin resistance can return a total LDL within the normal range with a large portion of those being very dense LDL particles.

A future article will address the assessment and management of insulin resistance-driven dyslipidemia in full.

Obesity and Metabolic Syndrome

Excess adiposity, particularly visceral fat, releases free fatty acids and pro-inflammatory cytokines that directly impair insulin signaling at the receptor and post-receptor level. As insulin resistance deepens, compensatory hyperinsulinemia takes over and chronic hyperinsulinemia promotes fat synthesis and inhibits fat mobilization simultaneously.

Hyperinsulinemia also drives central leptin resistance, impairing the hypothalamic satiety signal that would otherwise prevent excess caloric intake. The result is a system that is simultaneously storing more fat, burning less of it, and receiving a progressively degraded satiety signal.

Metabolic syndrome is the clinical name for the point at which this process becomes visible, is defined by the presence of these five findings: abdominal obesity, elevated fasting triglycerides, reduced HDL cholesterol, elevated blood pressure, and impaired fasting glucose.

Obesity is more responsive to lifestyle modification at the early stages, when increasing subcutaneous fat is first detected. As abdominal (visceral) fat begins accumulating, the self sustaining mechanisms makes loosing weight more difficult the longer you wait to make changes.

Obesity is extensively discussed in two articles elsewhere on this site: Part One and Part Two.

Polycystic Ovary Syndrome

Insulin resistance is present in the majority of women with PCOS regardless of body weight (Teede et al., 2018). Lean women with PCOS carry the same underlying metabolic driver. The hyperinsulinemia-CYP17A1-ovarian androgen axis operates independently of obesity which is why the condition’s metabolic trajectory parallels insulin resistance severity.

Women with PCOS carry substantially elevated lifetime risk of type 2 diabetes, cardiovascular disease, and non-alcoholic fatty liver disease, because all of them share the same metabolic root. The main management for this condition is the diabetes drug metformin, it addresses some of the pathways leading to insulin resistance.

If you are pre-menopausal woman with abdominal fat accumulation you need to take this seriously. Start aggressive lifestyle modification and seek additional testing from your doctor: specifically sex hormone-binding globulin (SHBG) levels.

Hypertension

Arterial hypertension is usually not associated by most people as related to insulin resistance. While there are other causes of hypertension, if you have abdominal obesity, abnormal lipids and/or pre-diabetes, your hypertension is likely the result of underlying insulin resistance.

Different mechanisms lead to insulin resistance mediated arterial hypertension.

• First, chronic hyperinsulinemia directly stimulates sympathetic nervous system outflow, raising heart rate and peripheral vascular resistance (Landsberg, Journal of Hypertension, 2001).

• Second, insulin acts on the proximal renal tubule to enhance sodium-hydrogen exchanger activity, promoting sodium retention, volume expansion, and the pressure increase that follows (DeFronzo, Diabetologia, 1981).

• Third, insulin resistance effects in the vascular endothelium is not uniform: the PI3K-eNOS-nitric oxide vasodilatory pathway is selectively impaired while the MAPK-endothelin-1 vasoconstrictive pathway is preserved. The net result is a shift in vascular tone toward vascular constriction (Muniyappa and Sowers, Reviews in Endocrine and Metabolic Disorders, 2013).

• Fourth, visceral adipose tissue generates angiotensinogen locally, activating the renin-angiotensin-aldosterone system and adding a fourth independent pressure-elevating mechanism to the three already operating.

Conventional antihypertensive therapy mostly addresses the pressure reading. With the exception of ACEI/ARB class medications, most of these mechanisms are left unaddressed. If you have unexplained (often called essential) hypertension, ask your doctor for a lipid and pre-diabetes screening if you haven’t already. If visible obesity is already present despite normal laboratories, aggressive lifestyle modification needs to be an active part of your treatment.

An Unescapable Reality

The metabolic syndrome caused by a single underlying insult, insulin resistance, is one the most striking clinical manifestation illustrating the interconnected nature of the human body. We have come to think the human body as a collection of separate independent systems: nervous, cardiovascular, gastrointestinal, etc. We have treated diseases based on this foundation for years. The reality is that our body is a collection of tightly interconnected systems, a failure in one has measurable effects on every other.

Six organ systems remain: the heart, the kidneys, the liver, the airway during sleep, the brain, and the relationship between insulin resistance and malignant transformation.

Found this article useful? Share your thoughts. Join the conversation below.

Educational content on The Metabolic Archives is free, because medical information should be accessible to everyone. If you find value and want to support the work, a paid subscription is available and genuinely appreciated. Visit the About Page for additional information.

Subscribe now

© 2026 The Metabolic Archives. All rights reserved.

Tags: insulin resistance, metabolic syndrome, type 2 diabetes, PCOS, hypertension, dyslipidemia, obesity, patient education

Why postprandial glucose matters

Blood glucose spikes after carbohydrate-containing meals happen in everyone, and is a stronger predictor of cardiovascular risk than fasting glucose in multiple large cohort studies. Much of the research behind these strategies was conducted in people with type 2 diabetes or pre-diabetes, because those populations show larger and more measurable glucose excursions.

Slowing Glucose Absorption

These eight strategies reduce the rate at which glucose arrives in your bloodstream. They work through different mechanisms including: delayed gastric emptying, physical barriers to intestinal absorption, reduced carbohydrate load, slower digestion. The result is a flatter postprandial glucose curve.

1. Eating order

What to do: At any meal containing carbohydrates, eat your protein and non-starchy vegetables first. Eat the carbohydrates last.

Why it works: Protein and fat at meal onset slow gastric emptying, delaying the arrival of glucose at the small intestine. Vegetable fiber forms a physical matrix in the proximal intestine that impedes glucose absorption. And the incretin hormones GLP-1 and GIP are primed before the carbohydrate load arrives, enhancing the insulin response to it.

What the evidence says: This is among the best-supported strategies in the toolkit. A 2015 pilot RCT by Shukla et al. in Diabetes Care (n=11, obese adults with T2DM) found glucose was reduced 29%, 37%, and 17% at 30, 60, and 120 minutes respectively with a carbohydrate-last meal order compared to carbohydrate-first, using the same foods. A 2020 study in Clinical Nutrition (Sun et al., n=16 healthy adults) extended the finding to normoglycemic individuals across five meal sequences and confirmed significant incretin effects. A 2023 crossover randomized control trial (RCT) in Nutrients (Imai et al., n=18 healthy young women) established food order dominates over eating speed; eating quickly with vegetables first produces a better glucose outcome than eating slowly with carbohydrates first.

One practical point: this requires actual sequential separation. A mixed plate with everything on the fork at once does not produce the same effect.

Limitation: Most acute studies use controlled laboratory meals. Ecological validity in free-living conditions is an active research question. Long-term glycemic control data are limited, though a 16-week behavioral RCT in pre-diabetes (Shukla et al., Diabetes, Obesity and Metabolism, 2023) showed a trend toward HbA1c improvement with carbohydrate-last counseling.

2. Vinegar before the meal

What to do: One to two tablespoons of any vinegar containing 4-6% acetic acid, diluted in a full glass of water, consumed 5-20 minutes before a carbohydrate-containing meal. Eating a simple salad with a vinaigrette will have similar effectiveness as long as is consumed first before bread or any other food.

Why it works: Three independent mechanisms. Acetic acid inhibits salivary and pancreatic alpha-amylase and intestinal disaccharidases, the enzymes that break starch and disaccharides into absorbable glucose; this mechanism is similarly to the diabetes medication acarbose. It also delays gastric emptying, and at higher doses, enhances insulin-stimulated skeletal muscle glucose uptake through AMP-kinase activation.

What the evidence says: A 2017 systematic review and meta-analysis by Petsiou et al. in Diabetes Research and Clinical Practice (11 RCTs) found significant attenuation of postprandial glucose and insulin in both healthy individuals and metabolically unhealthy populations. Acute postprandial benefit is well-established. A 2025 GRADE-assessed meta-analysis in Frontiers in Nutrition (Khezri et al., 7 RCTs, n=463 T2DM patients) found significant improvements in fasting glucose and HbA1c with longer-term use, though five of seven studies involved Iranian populations, and four were unblinded.

Contraindications: This intervention requires physician oversight in anyone with gastroparesis or active peptic disease, and in patients on insulin or sulfonylureas, where the glucose-lowering effect creates meaningful hypoglycemia risk.

3. Starches, the cook-cool method

What to do: Cook rice, potatoes, or pasta. Refrigerate at 39°F (4°C) for approximately 24 hours before eating. Reheating is acceptable.

Why it works: When starchy foods cool at refrigerator temperature, amylose and long amylopectin chains reorganize into double-helical crystalline structures that amylase cannot efficiently hydrolyze. This is retrogradation, the conversion of digestible starch to Resistant Starch Type 3 (RS3). RS3 passes through the small intestine largely intact, reaching the colon where it is fermented by gut bacteria to short-chain fatty acids including butyrate. Less glucose is absorbed per serving.

What the evidence says: A 2015 randomized crossover study by Sonia et al. in the Asia Pacific Journal of Clinical Nutrition (n=15 healthy adults) found that 24-hour refrigeration at 4°C increased resistant starch content of white rice from 0.64 to 1.65 g/100g and significantly lowered the postprandial glycemic response. A 2021 systematic review and meta-analysis in the American Journal of Clinical Nutrition (Cai et al., 25 RCTs, n=745) confirmed significant reductions in postprandial glucose and insulin across resistant starch interventions.

First, refrigeration at 4°C for approximately 24 hours is required for a clinically meaningful RS increase. Second, reheating partially reverses amylopectin retrogradation but not amylose retrogradation, so net resistant starch content remains meaningfully higher than in freshly cooked starch. Rice and pasta show consistent results; potato data is more mixed.

Safety note: A 2022 RCT in Nutrition & Diabetes (Strozyk et al., n=32 T1DM patients) found cooled rice produced significant increases in hypoglycemic episodes when insulin dose was not adjusted. Patients using insulin should consult their physician before using this technique.

4. Oats, the processing hierarchy

What to do: Choose steel-cut oats or thick rolled (old-fashioned) oats. Avoid instant oats.

Why it works: The active constituent responsible for oats’ glucose-attenuating effect is beta-glucan, a soluble fiber that forms a viscous gel in the gut, slowing gastric emptying and glucose absorption. Beta-glucan’s efficacy depends entirely on its molecular weight and structural integrity both destroyed by industrial processing. High heat and mechanical processing fragment the beta-glucan molecules, producing less viscosity and less glycemic attenuation.

What the evidence says: A 2021 systematic review and meta-analysis in the Journal of Nutrition (Musa-Veloso et al.) is definitive on this point. Intact oat kernels and thick rolled oats significantly reduce postprandial glucose and insulin responses. Thin, quick, and instant oat flakes produced no significant effect. The hierarchy is clear and clinically meaningful: steel-cut oats (GI approximately 42-50) and thick rolled oats (GI approximately 55) work. Quick oats are marginal. Instant oats provide no meaningful glycemic benefit, they are functionally similar to processed grain.

Flavored instant oat packets add sugar to a product that has already lost its primary mechanism of benefit and should be completely avoided.

One practical note for readers already using this strategy: overnight oats prepared by soaking thick rolled oats in cold liquid overnight develop resistant starch through retrogradation, combining two mechanisms from this toolkit in a single preparation.

5. Soup or broth as a meal opener

What to do: Start a meal with a low-energy-density broth-based soup: vegetable broth, miso, or a light bone broth.

Why it works: The mechanism here is indirect. A low-energy-density liquid consumed before a meal causes gastric distention and triggers early satiety hormone release (CCK, GLP-1 via volume and nutrient sensing), reducing total energy intake at the subsequent meal. Less food consumed means less carbohydrate consumed, which produces a smaller glucose excursion.

What the evidence says: A 2007 randomized crossover trial by Flood and Rolls in Appetite (n=60 normal-weight adults, five-week study) found that all soup forms tested reduced subsequent test meal intake by approximately 20% (134 kcal) compared to no preload. A 2018 study in Nutrients by Lim et al. (n=32 healthy lean males) confirmed that low-energy-density savory broth preloads reduced subsequent lunch intake, while high-energy-density preloads produced larger postprandial glucose spikes. A cream-based, high-calorie starter defeats the purpose entirely.

6. Water preload

What to do: Drink 500 mL (approximately 17 oz, or two full glasses) of plain water 30 minutes before your meal.

Why it works: Plain water consumed before a meal activates gastric mechanoreceptors that generate satiety signaling. The absorption window from the stomach is approximately 15-30 minutes, which is why the 30-minute pre-meal timing matters.

What the evidence says: A 2008 study in the Journal of the American Dietetic Association (Davy et al., n=24 obese older adults) found approximately 13% reduction in meal energy intake with a 500 mL water preload versus no preload. A 12-week RCT in Obesity (Parretti et al., 2015, n=84 obese adults) found the practice produced 1.3 kg greater weight loss than control over the study period.

There is no direct glycemic RCT evidence for water preloading. The glucose benefit is entirely inferential from reduced meal size.

7. Portion reduction

What to do: At restaurants, share a main course or set half aside as next-day leftovers before you start eating. At home, serve yourself less and wait before going back.

Why it works: The dose-response relationship between carbohydrate load and postprandial glucose excursion is direct. Less carbohydrate consumed in a single sitting produces a smaller glucose curve. The additional finding from the meal-splitting literature is that consuming the same total carbohydrate load in two smaller sittings separated by time produces a significantly smaller glucose response than consuming it all at once.

What the evidence says: A 2020 five-day crossover laboratory study in the International Journal of Behavioral Nutrition and Physical Activity (Hollands et al., n=30) found that 25-50% portion reductions significantly reduced daily energy intake without compensatory eating at subsequent meals.

8. Slow eating

What to do: Extend the duration of your meal deliberately. Put the fork down between bites. The specific target is to give satiety signaling time to develop before the meal ends.

Why it works: Satiety hormones including PYY and GLP-1 are released progressively as food moves through the gastrointestinal tract. Their signaling takes time to reach the brain, eating quickly outpaces the signal, allowing more food to be consumed before fullness registers. Slower eating also allows the anticipatory physiological response to food that includes insulin release and digestive enzyme secretion to develop more fully.

What the evidence says: A CGM-based RCT in Nutrients (Imai et al., 2020, n=17 healthy women) found that fast eating produced approximately double the glucose area under the curve compared to slow eating across multiple daily meals.

Increasing Glucose Uptake

9. Post-meal walking

What to do: Walk for 10-15 minutes within 30 minutes of finishing a meal. Even 1-3 minutes of stair climbing works.

Why it works: Contracting skeletal muscle translocates GLUT4 glucose transporters to the cell surface through a pathway that is independent of insulin signaling. This is a direct response to muscle contraction during the postprandial absorption window.

What the evidence says: A 2025 RCT in Scientific Reports (Hata et al., n=12, randomized crossover) found that a 10-minute walk immediately after glucose intake produced essentially the same 2-hour glucose area under the curve (AUC) reduction as a 30-minute walk started later. A 2013 RCT in Diabetes Care (DiPietro et al., n=10 older adults at IGT risk) found that three 15-minute post-meal walks were superior to a single 45-minute continuous walk for 24-hour glycemic control. A 2024 RCT in PLOS ONE (Batacan et al., n=31) found that even 1-3 minutes of stair climbing post-meal produced significant reductions in both glucose and insulin.

A 2025 systematic review in Frontiers in Nutrition confirmed that resistance movements may produce especially potent effects via greater type II muscle fiber recruitment, for readers who prefer brief strength work to walking.

A note on timing: when you eat matters

Insulin sensitivity follows a robust circadian rhythm, peaking in the morning and declining through the afternoon and evening. The same glucose load eaten at breakfast produces a lower postprandial excursion, a lower insulin requirement, and a higher thermic effect of food than the same meal eaten at dinner.

A randomized crossover trial by Yoshizaki et al. in Nutrients (2021) found that a three-hour difference in dinner timing (6pm versus 9pm) significantly improved 24-hour glucose profiles. A 5-week RCT by Sutton et al. in Cell Metabolism (2018, n=8 prediabetic men) found that early time-restricted eating (6:30am to 3pm) improved insulin sensitivity, blood pressure, and oxidative stress without any caloric restriction or weight loss.

The practical implication: the common intermittent fasting pattern of skipping breakfast and eating from noon to 8pm is a late eating window. It may forfeit or actively reverse the primary metabolic advantage of time-restricted eating by concentrating caloric intake in the period of lowest circadian insulin sensitivity. If you already limit your eating window, the evidence favors making it earlier rather than later.

Layering, not stacking

These “hacks” are simple to implement and produce modest though measurable improvement in post-meal glucose peak and total caloric intake per meal. But they are not mutually exclusive, in fact evidence supports additive benefit from consistent use of several that fit into your existing routine. Each one you add creates overlap with the others at the physiological level.

These strategies attenuate the postprandial glucose curve. They do not replace sound dietary patterns. They are not a substitute for medication in people who need it. They do not produce the metabolic changes that caloric reduction, structured exercise, and improved sleep quality produce.

You can grab a handy pocket reference here.

Found this article useful? Share your thoughts. Join the conversation below.

Educational content on The Metabolic Archives is free, because medical information should be accessible to everyone. If you find value and want to support the work, a paid subscription is available and genuinely appreciated. Visit the About Page for additional information.

Subscribe now

© 2026 The Metabolic Archives. All rights reserved.

The headline landed this week: U.S. public debt has crossed 100% of GDP for the first time since World War II. The post-WWII debt was the residue of an existential war with a defined endpoint. It was financed through long-duration fixed bonds, and followed by the most productive economic expansion in American history. None of those conditions exist today.

The Debt You Can See, the Debt You Cannot

The federal government reports its public debt as the total of Treasury bills, notes, and bonds outstanding. But as any good magician, they keep the rest hidden from you.

Unfunded liabilities are the present value of benefits the federal government has legally promised to pay, primarily through Social Security and Medicare, in excess of revenues projected to fund them.

Per the FY2024 Financial Report, total formal federal liabilities stand at $45.5 trillion (U.S. Treasury / GAO / OMB, FY2024 Financial Report). The present value of unfunded Social Security and Medicare obligations over 75 years adds another $78.3 trillion. Combined, total federal obligations reach $123.8 trillion. Far surpassing GDP years ago.

The Alarm That Rang in 2001

The 2001 Treasury Financial Report estimated total unfunded liabilities for Social Security and Medicare at $11.1 trillion, producing a combined federal obligation of approximately 105% of GDP (U.S. Treasury Financial Report, 2001; Capretta, American Enterprise Institute, November 2022). Public debt that year was approximately $5.8 trillion, or 55% of GDP.

By 2021, Social Security’s actuarial deficit had grown from $4.6 trillion to $22.7 trillion. Medicare’s unfunded liability had grown from $12.8 trillion to $40.5 trillion. Combined Social Security and Medicare unfunded liabilities in 2021 reached $93.1 trillion, approximately 400% of GDP (Capretta, AEI, longitudinal analysis of Treasury Financial Reports, 2001-2021).

Maya MacGuineas, president of the Committee for a Responsible Federal Budget, described the 100% GDP crossing last week as a “bipartisan abdication”; a position I hold as true.

The National Credit Card

The debt ceiling periodically enters public debate as either a fiscal discipline mechanism or a constraint; some argue for its elimination.

The debt ceiling functions like the fixed credit limit on a VISA card, while the other option is the equivalent of switching to an AMEX with no preset spending limit. Hand either card to someone with no spending discipline and ask yourself, which produces more debt over any given timeframe.

The debate about the ceiling is a distraction from the spending behavior it was meant to constrain.

The Point of No Return

In 2025, the United States paid $970 billion in interest on its national debt (Peter G. Peterson Foundation, Monthly Interest Tracker, April 2026). That figure already exceeds annual defense spending. The Congressional Budget Office projects net interest payments will rise from $1.0 trillion in 2026 to $2.1 trillion by 2036, totaling $16.2 trillion over the next decade. Interest costs as a share of federal revenues reached 18.5% in 2025 and are projected to reach 25.8% by 2036.

The CBO’s most recent Budget and Economic Outlook projects debt held by the public will rise from 100% of GDP now to 118% by 2035 and to 120% by 2036 under current law (CBO, 2025-2035 Outlook, February 2026). The Congressional Budget Office has noted that the One Big Beautiful Bill Act, combined with higher tariffs and lower immigration rates, are cited as drivers of acceleration beyond the baseline (The Hill, May 1, 2026).

Can We Inflate Our Way Out?

Post-WWII debt reduction was aided meaningfully by inflation eroding the real value of long-duration fixed bonds. Today’s federal debt is predominantly short-duration. It must be refinanced frequently at prevailing market rates. Sustained inflation now triggers higher refinancing costs almost immediately, partially neutralizing the benefit that made inflation an effective tool in the 1940s and 1950s.

In addition inflation as a debt-reduction mechanism is a non-legislated tax imposed on people unable to afford it. It drives the value of their salary and savings down through increasing consumer prices.

Can We Tax Our Way Out?

The top 1% of earners reported approximately $3.3 trillion in adjusted gross income in 2022. Theoretical confiscation of every dollar in income covers less than two years of current deficit spending and makes no dent in the principal.

Three compounding consequences follow from aggressive high-earner taxation at scale.

First, capital flight. California lost a net $24 billion in adjusted gross income to out-migration in 2021, with Texas and Florida as primary destinations; the California Legislative Analyst’s Office has explicitly flagged revenue volatility from high-earner concentration as a structural budget risk (IRS Statistics of Income Migration Data, 2021; California LAO fiscal risk assessments). New York City’s top 1% of earners pay approximately 50% of the city’s income tax revenue, creating structural fragility from even modest high-earner emigration.

Second, capital formation. Venture capital, angel investors, and small business funding flow disproportionately from high-net-worth individuals. Compressing that capital through aggressive taxation decreases the pipeline from investment to employment and innovation.

Third, innovation suppression. The promise of financial reward in exchange for risk is the engine of entrepreneurial activity. Remove the reward sufficiently, and you reduce the risk-taking. The result is fewer new businesses, a contracting job market, and an unemployment crisis that becomes its own fiscal catastrophe.

The debt problem cannot be solved by taxing the top earners alone, without concomitant spending discipline.

The Healthcare Collision — Why This Is Personal

The federal government is the dominant payer in American healthcare. Medicare covers 67 million Americans. Medicaid covers 80 million. Together they represent roughly 40% of all U.S. healthcare spending.

The June 2025 Medicare Trustees Report projects depletion of the Hospital Insurance Trust Fund by 2033, three years earlier than the 2024 projection of 2036 (2025 Annual Report of the Boards of Trustees, Federal Hospital Insurance and Federal Supplementary Medical Insurance Trust Funds). At depletion payroll tax revenues would cover approximately 89% of scheduled Part A benefits. That is an automatic 11% reduction in payments to hospitals and providers.

This depletion date has been extended by Congress twenty times over forty years. It is also becoming progressively more expensive to repeat. The gap between promised benefits and dedicated revenues is widening with each passing year. The ratio of workers supporting each beneficiary has fallen from approximately 5:1 in 1960 to 2.7:1 today (Social Security Administration Trustees Reports; CBO Long-Term Budget Outlook).

The CBO projects that mandatory spending will consume the entirety of federal revenues by the mid-2030s under current trajectory; discretionary spending would become entirely debt-financed by then. Fiscal mandatory expenditures are driven by the dual pressures of chronic disease prevalence and demographic aging; approximately 60% of American adults have at least one chronic condition; 40% have two or more (CDC, National Center for Chronic Disease Prevention and Health Promotion).

The Bill, and Who Pays It

Every reader who has ever spent beyond their means knows what happens next. The federal government has done exactly that for years with no change in sight. Every year of continued inaction narrows available options and increase required corrections in the future.

Found this article useful? Share your thoughts. Join the conversation below.

Educational content on The Metabolic Archives is free, because medical information should be accessible to everyone. If you find value and want to support the work, a paid subscription is available and genuinely appreciated. Visit the About Page for additional information.

Subscribe now

© 2026 The Metabolic Archives. All rights reserved.

An independent physician was a small business owner with one client: the patient. The physician’s income, and professional reputation depended entirely on the quality of care delivered to the person across the desk. The obligation ran directly from physician to patient, and nothing stood between them. The physician’s and the patient’s interest were aligned, this was the unspoken covenant at the center of the patient-doctor relationship.

The Arithmetic That Ended It

The financial equation of independent practice begin to fail as overhead grew faster than reimbursement, neither variable within the physician’s control.

Rising malpractice insurance, expanding administrative staff to manage billing complexity, the expanding coding infrastructure required by insurer and Medicare, electronic medical record systems mandated by federal law after 2009. These costs compounded over years while reimbursement rates from insurers and Medicare barely kept pace.

Medical practice is and shall always be a service business, anchored in the sacred relationship between doctors and patients. But when overhead outpaces revenue in any business, options are limited:

• Increase prices — unfortunately the insurance pay model caps reimbursement with limited opportunity for price flexibility.

• Add ancillary services — requires adequate staff capacity and access to capital for initial technology investment. Those costs plus your extra time investment need to be balanced against expected additional revenue produced, which is mostly determined by insurance reimbursement rates.

• Reduce overhead — most of these are not entirely within the practice’s control.

• Increase encounter volume — involves reducing time per patient visit, at the risk of trading quality for quantity.

Or, you can leave private practice entirely.

Around 1998 I transitioned to a hospital affiliated practice, in essence becoming a corporate employee. This practice allowed adequate time for meaningful patient encounters while the administrative burden of running a small business transferred to the institution. The trade seemed reasonable: give away some clinical autonomy in exchange for financial stability while upholding my personal patient care standards.

And for a while, it was.

What Health Coverage Actually Is

Health insurance is not insurance in the traditional sense. Traditional insurance covers low-probability, high-cost events: your house burning down, a car accident. The actuarial model works because most people never file a claim.

Health coverage is different. Every human being will consume healthcare, the only variables are timing and amount. This industry is basically a prepaid consumption mechanism operating inside an insurance’s legal structure.

When the Affordable Care Act eliminated several of the tools the industry had used to manage profitability under that structure — pre-existing condition exclusions, lifetime benefit caps, certain coverage exclusions — the industry rapidly adapted. Networks narrowed, deductibles rose, prior authorization expanded to areas not previously covered. Understanding this explains the experience patients have when dealing with a financial model trying to preserve its margin in a market where everyone eventually files a claim.

A National Wave

According to the Congressional Research Service, the portion of independent physicians fell from 57% in 2000 to 43% by 2009, with projections in 2012 already anticipating a further drop to 33% within a year (Congressional Research Service, Report R42880, 2013).

By 2022, 74% of all US physicians were employed by either a hospital system or another corporate entity. More than 55% are hospital-employed; another 23% work for other corporate owners, including private equity firms (Society of Actuaries, Health Care Provider Consolidation and Shortages, 2023; Health Affairs Forefront, 2023). Between 2012 and 2021, private equity firms completed 1,094 unique acquisition transactions involving US physician practices (Society of Actuaries, 2023).

The Same Pressures, New Instruments

The early years of hospital affiliated practice felt like a return to what medicine was supposed to be. The trade felt reasonable, but was not permanent.

As reimbursement constraints tightened against hospital overhead, the emphasis inside hospital systems shifted progressively from clinical outcomes to throughput. New targets appeared requiring increasing encounter numbers, intensified pressure to shorten hospital length-of-stay; the overall objective became discharging patients faster, freeing beds for the next paying clients. Discharge decisions gradually became logistical ones, driven mostly by the system’s needs.

Early throughput targets came with positive incentives: bonus compensation for meeting productivity benchmarks. What followed was financial penalties for failing to comply with the established targets. The moment the penalties materialized was the point the system crossed a line, a line my ethics and conscience could not cross.

My decision to retire was born out of that realization.

Who Bore the Cost

According to data presented at the American Heart Association’s 2025 scientific sessions, adjusted all-cause 30-day readmission rates increased for patients in the lowest and middle income quartiles between 2010 and 2019. During the same period, readmission rates decreased among patients in the highest income quartile (American Journal of Managed Care, November 2025). The federal Hospital Readmissions Reduction Program’s measured improvements in readmission rates were achieved disproportionately among wealthier patients.

Premature discharge hits those least equipped to self-manage between discharge and full recovery the hardest: those with limited financial resources, health literacy, support system at home, lacking the tools to navigate the complexities of our modern healthcare system.

While readmission data is observational, socioeconomic factors are themselves risk factors for readmission. The casual association between early discharge and increased readmission rates in this population, is both strong and consistent with my own anecdotal observations.

The Liability Trap

Prior authorization denials by insurance companies carry no formal malpractice exposure for the insurer. Discharge targets set by hospital administrators are not reviewed by medical boards. Corporate compensation structures that tie physician pay to bed turnover do not appear on the death certificate when a patient readmits and dies.

Full legal accountability still lands on the party whose clinical authority was systematically reduced. I want to be clear here: regardless of any pressure or constraints, physicians should be fully accountable for every clinical decision they make. However, when said decisions carry a threat of penalties from third parties with a financial interest in the results, it would be equitable to distribute the legal responsibility among all players involved.

Burnout Is Not a Wellness Problem

Depending on survey methodology and timing, between 48% and 58% of US physicians report burnout, significantly above the pre-pandemic baseline of approximately 40% in 2018 (AMA National Physician Burnout Survey, 2024; Physicians Foundation Survey, 2023; Stanford Medicine, April 2025). Among physicians still in training, the rate is 61%, and among medical students it is 71% (Physicians Foundation, 2023). In 2024 alone, 27% of medical groups reported a physician leaving or retiring early due to burnout (MGMA Stat Poll, September 2024).

A really somber statistic: more than half of US physicians know of a colleague who has considered, attempted, or died by suicide. One in five know of a colleague who has done so within the past twelve months (Physicians Foundation, 2023).

A Brief Acknowledgment

In 2020, physicians and nurses entered clinical environments they knew were dangerous, and did so knowing they lack adequate protective gear. They showed up because professional duty required it. Some of them never made it out; people I knew, friends, colleges.

What You Lost and May Not Been Able to Name

If you moved to an employed provider inside a health system in the past two decades, you probably experienced something different: shorter office visits, earlier hospital discharges, referral to institutional affiliated consultants and services.

What feels like a failure of the relationship between you and your doctor is a failure of the healthcare system. The physician is not withholding time and attention, is operating inside a system that has restructured both.

Found this article useful? Share your thoughts. Join the conversation below.

Educational content on The Metabolic Archives is free, because medical information should be accessible to everyone. If you find value and want to support the work, a paid subscription is available and genuinely appreciated. Visit the About Page for additional information.

Subscribe now

© 2026 The Metabolic Archives. All rights reserved.

A federal judge listens for nearly seven hours as mothers describe burying sons, a teenager describes being born into withdrawal and losing his mother to opioids, and person after person describes years of addiction that began with a prescription.

The judge is visibly moved, then she approves the negotiated sentence.

The company will pay $225 million, the amount the federal government agreed to actually collect from a paper penalty of $5.5 billion. The Sackler family will contribute up to $7 billion over fifteen years, from future earnings. Victims will receive between $8,000 and $16,000, if they can prove they were prescribed OxyContin.

The judge said it plainly: ”It is not lost on me that those who started the epidemic will not serve a sentence.”

Death toll linked to the epidemic since 1999: 900,000.

Individuals criminally prosecuted: zero.

Where It Began

OxyContin launched in 1996 on two claims. First, that it provided twelve hours of consistent pain relief, making it safer than shorter-acting opioids. Second, that its addiction potential was less than one percent in patients treated for pain.

Both were known to be false by Purdue’s own leadership before the drug reached the market. According to a peer-reviewed case study published in PMC (Paremoer et al., PMC12344885) and the Harvard Public Health Review (Chow R, 2021, DOI:10.54111/0001/Y5), the addiction risk in chronic non-cancer pain populations has since been established at 20 to 50 percent across multiple studies. The twelve-hour duration claim was contradicted by the company’s own pharmacokinetic data.

Before OxyContin, opioids were prescribed primarily for cancer pain and end-of-life care. Purdue’s strategy deliberately expanded prescribing into chronic non-cancer pain, a larger population never treated with long-term opioids at scale before. They did this using the “pain as the fifth vital sign” campaign of the late 1990s that created the permissive prescribing climate that Purdue then weaponized.

At a 1996 sales rally, Richard Sackler called for “a blizzard of prescriptions.” Internal documents show the first-year sales goal was hit four months ahead of schedule. By September 1996, Sackler was personally monitoring whether physician dinner programs were cost-effective in driving prescription volume: physicians who attended wrote more than double the OxyContin prescriptions than those who didn’t.

The Machinery

A paid speakers program compensated physicians to prescribe and promote OxyContin at events designed to look like medical education. An electronic medical records company was paid to identify and target patients for increased opioid prescriptions. Fake grassroots pain advocacy organizations were constructed to simulate independent patient demand. Academic and hospital institutional relationships were cultivated to purchase scientific credibility.

Inside the company, more than one hundred internal memos from 1997 to 1999 contained the words “street value,” “crush,” or “snort” (DOJ Western District of Virginia, press release, May 10, 2007; STAT News document archive, December 2019). By March 2000, the company had received reports of OxyContin abuse, sales staff continued unrestricted promotion. As late as 2013 and 2014, McKinsey was advising Purdue on how to target the highest-volume prescribers and increase sales representative visit quotas.

A separate physician group was deceived by falsified safety data about OxyContin. They were deceived deliberately, by a company that knew the truth and withheld it. However a Schedule II opioid claiming less than one percent addiction potential should have generated clinical skepticism.

A 2012 study in the New England Journal of Medicine found that 76 percent of those seeking treatment for heroin addiction had begun with pharmaceutical opioids, primarily OxyContin.

The Reckoning That Wasn’t

By 2006, career prosecutors at the Department of Justice had built a felony case including wire fraud, money laundering, and conspiracy, targeting Purdue executives who had knowingly misled physicians, patients, and regulators.

Purdue retained Rudy Giuliani’s firm to negotiate with the political leadership of the Bush Justice Department. Giuliani’s firm simultaneously held a $1 million consulting contract with the DOJ itself (Time magazine investigative report, 2018; Fierce Pharma, August 27, 2018; American Oversight FOIA documentation).

After a closed-door meeting, the felony indictments disappeared. Three executives, President Michael Friedman, General Counsel Howard Udell, and former Chief Medical Officer Paul Goldenheim, pleaded guilty to misdemeanor misbranding. They performed community service and paid fines totaling $34.5 million across the three. The company pleaded to felony misbranding and paid $600 million, approximately 90 percent of OxyContin profits during the offense period (DOJ Western District of Virginia, May 10, 2007; U.S. Senate hearing transcript, CHRG-110shrg40884).

OxyContin sales the following year: $2.2 billion. By 2010: more than $3 billion annually.

Two U.S. senators, Hassan and Whitehouse, spent years demanding the prosecution memo. The DOJ refused to release it (Senate letters, August 2018 and September 2019). The memo has never been made public.

What the Family Took

Between 1995 and 2007, the Sackler family extracted $1.3 billion from Purdue. In the decade following the first guilty plea they extracted $10.7 billion, much of it moved into offshore accounts and trusts beyond the reach of American creditors. Ninety percent of those distributions derived directly from OxyContin revenue (AlixPartners bankruptcy audit report; U.S. House Committee hearing transcript, CHRG-116hhrg43010, confirmed under congressional testimony by David Sackler).

In September 2014, Mortimer Sackler emailed a family member that Purdue was in “a death spiral.” Jonathan Sackler responded that they had “taken a fantastic amount of money out of the company.”

The Architecture of Impunity

The Sackler family contributed more than $1.6 million to federal candidates and officials, distributed across both parties (OpenSecrets/Center for Responsive Politics, April 4, 2019). Purdue donated more than $500,000 to the Republican Attorneys General Association in 2016 and $125,000 in 2018, an organization supportive of the lenient settlement terms (The Intercept, July 7, 2020; August 13, 2021). Lobbying spend peaked at $1.12 million in 2018, using nine revolving-door lobbyists. Contributions to both parties’ attorneys general associations continued during active bankruptcy proceedings. Unsurprisingly, no direct quid pro quo was ever proven.

Ed Bisch, who lost his son Eddie to an overdose in 2001, stood outside the courthouse holding a sign: “Punishable by fine means legal for a price.”

What the Resolution Actually Means

A $5.5 billion criminal sentence, of which $225 million will actually be collected by the federal government. A Sackler family contribution of up to $7 billion, paid from future earnings over fifteen years, not from the $10.7 billion already extracted and moved offshore. The settlement across all parties totals approximately $50 billion, most designated for opioid remediation through government entities. Individual victim compensation is only expected to be around $8,000 to $16,000, contingent on documentation.

Alexis Pluis, an upstate New York mother who lost her son to opioids in 2014, testified today that she expects to receive nothing because she cannot locate the twenty-three-year-old prescription records required to prove her claim. She stated: ”We still deserve justice, and this isn’t it.”.

The Argument, Stated Directly

Federal drug law prosecutes the street dealer and the cartel kingpin on the same conspiracy theory. In their 2020 guilty plea, Purdue’s executives admitted that they “knowingly and intentionally conspired and agreed with others to aid and abet” illegal prescribing (U.S. Department of Justice, Criminal Division, November 24, 2020). The decision not to prosecute individuals was a choice made by people with access to the people making decisions, and the resources to hire those with that access.

What happened to Purdue Pharma is not just the story of one corrupt company finally brought to account. It also the story of what money and access can purchase in the American legal system.

Nine hundred thousand deaths. No prison sentences.

Found this article useful? Share your thoughts. Join the conversation below.

Educational content on The Metabolic Archives is free, because medical information should be accessible to everyone. If you find value and want to support the work, a paid subscription is available and genuinely appreciated. Visit the About Page for additional information.

Subscribe now

© 2026 The Metabolic Archives. All rights reserved.

Tags: opioid epidemic, Purdue Pharma, Sackler family, institutional accountability, pharmaceutical fraud, public health policy, opinion

The Invisible Phase

When peripheral tissues begin resisting insulin’s signal, the pancreatic beta cells respond by producing more insulin. Your fasting glucose is normal, HbA1c is reassuring, your doctor review the numbers with you; everything looks fine. And yet something is wrong. You feel it, your waistline shows it, your energy contradicts it. The pancreas is already working at supra-physiological levels to hold those number in place.

You are not imagining things!

That gap between what routine tests detect and what is actually happening in your body is one of the most consequential blind spots in modern preventive medicine. You may be years into a progressive metabolic deterioration that standard screening cannot see.

The Diagnostic Gap

HbA1c reflects average glucose over the preceding 90 days. Aftermeal glucose spikes, the earliest detectable form of glucose dysregulation, are diluted into the average and disappear. The test is also unreliable in condition affecting red cell lifespan: hemolytic anemia, iron deficiency anemia, hemoglobinopathies including sickle cell trait. In these patients, HbA1c can be systematically misleading in either direction. As Gallagher et al. noted in the Journal of Diabetes (2009), HbA1c has well-documented limitations as an early detection tool, particularly for capturing postprandial dysregulation.

Fasting glucose is a late-stage marker. By the time fasting glucose climbs above the diagnostic threshold, a significant portion of beta cell functional reserve is already lost. Fasting glucose turning diagnostic means the most reversible window for insulin resistance has already passed.

The actual tool that captures what these two miss is the 2-hour oral glucose tolerance test (OGTT). By measuring glucose response at two hours after a standardized 75-gram carbohydrate load, the OGTT detects impaired glucose tolerance today, not years in the future. The DECODE Study Group (2001), analyzing data across European cohorts, demonstrated that 2-hour post-load glucose was a stronger predictor of cardiovascular mortality than fasting glucose. The OGTT fell out of routine clinical use for practical reasons: it requires a two-hour patient visit, careful standardization, and coordination that a fasting blood draw does not.

The implication for you: have you have been screened with the right tool. For early metabolic dysfunction detection, OGTT is the right tool.

HOMA-IR Another Useful Tool

A calculated tool available from standard lab values is HOMA-IR (Homeostasis Model Assessment of Insulin Resistance): fasting glucose (mg/dL) multiplied by fasting insulin (µIU/mL), divided by 405. Validated against the euglycemic hyperinsulinemic clamp as reference standard by Matthews et al. in Diabetologia (1985), HOMA-IR provides an estimate of hepatic insulin resistance from two routine values. Its limitation is that it captures only the fasting, hepatic component of resistance missing peripheral postprandial dysregulation. Its utility is also constrained by the lack of standardized insulin assays across laboratories and population-specific threshold variation.

The Self-Sustaining Loops

Loop One: Pancreatic Compensation and Beta Cell Failure

Compensatory hyperinsulinemia is initially effective, but the beta cell paying for that effectiveness is operating at supra-physiological secretory output in an environment of chronic low-grade inflammation, elevated free fatty acids (FFAs), and progressive glucose toxicity. That environment is not sustainable indefinitely.

Glucolipotoxicity is the specific combined toxicity from chronic exposure of beta cells to glucose elevation and free-fatty acids (FFA). As Poitout and Robertson demonstrated in Endocrine Reviews (2008), neither insult alone produces the same degree of damage as their combination. Glucose toxicity impairs insulin gene expression and secretory function. FFA toxicity, through ceramide accumulation and mitochondrial uncoupling, drives beta cell loss (apoptosis). Together, they produce a rate of beta cell loss that neither would generate independently.

When adipose tissue reaches its fat threshold, genetically determined storage limit, fat begins depositing in non-adipose organs, including the pancreas. Taylor’s twin cycle hypothesis, developed and tested through the DiRECT trial and subsequent work published in Cell Metabolism (2018), established that intra-pancreatic fat accumulation is linked to beta cell dysfunction, and significant caloric restriction can restore meaningful beta cell function in earlier-stage disease. The operative word is remission, not reversal. Beta cell function can be recovered. Beta cell mass, once lost, cannot be meaningfully regenerated with current therapeutic tools.

Chronically hyperstimulated beta cells overproduce islet amyloid polypeptide (IAPP), which misfolds and aggregates into amyloid deposits within the islet architecture. As reviewed by Westermark et al. in Physiological Reviews (2011), this deposition is directly toxic to beta cells and disrupts the cellular organization of the islet, impairing both insulin secretion and local paracrine signaling.

Take away point: insulin resistance reversibility window is real and achievable with aggressive lifestyle modification. Reversibility is more successful with early rather than late interventions; early and accurate diagnosis with OGTT is your best option.

Loop Two: Hyperglycemia as Inflammatory Driver

Advanced glycation end products (AGEs) form when glucose binds non-enzymatically to proteins and lipids in a concentration-dependent process. AGEs accumulate in vessel walls, lens, kidney, and nerve tissue, and activate the receptor for AGEs (RAGE). RAGE activation drives NF-κB, the master inflammatory transcription factor, generating endothelial dysfunction, vascular stiffening, and sustained pro-inflammatory cytokine output. Brownlee’s foundational synthesis in Diabetes (2005) unified these pathways under a single mechanistic framework: mitochondrial superoxide overproduction under glucose excess as the upstream driver of all major pathways of diabetic complication.

HbA1c is an early form of AGE, and is usually normal in early stages of metabolic dysfunction, rising along as the metabolic dysfunction progresses with time.

The polyol pathway operates in parallel. In insulin-independent tissues, nerves, retinal cells, kidney, excess glucose is reduced to sorbitol by aldose reductase, consuming NADPH in the process. NADPH depletion impairs glutathione regeneration, reducing the cell’s primary antioxidant defense. Osmotic stress from sorbitol accumulation compounds the damage.

As detailed by Brownlee in Nature (2001), this pathway is a primary contributor to the microvascular and neuropathic complications of chronic elevated glucose.

Loop Three: Dyslipidemia as Amplifier

Insulin normally suppresses hepatic very-low density lipoprotein (VLDL) secretion and upregulates lipoprotein lipase-mediated VLDL clearance. When the liver becomes insulin resistant, both arms fail: VLDL secretion increases through uninhibited de novo lipogenesis, and clearance falls; blood triglycerides then rise. The triglyceride-enriched environment drives CETP-mediated exchange of triglycerides into high-density lipoprotein (HDL) particles, which are then rapidly cleared, reducing HDL. Hepatic lipase acts on the resulting triglyceride-enriched low-density lipoproteins (LDL), producing the small, dense, highly atherogenic LDL particles. And so, the classical lipid pattern of insulin resistance — elevated triglycerides, reduced HDL, small dense LDL — takes hold.

As detailed by Taskinen and Borén in Atherosclerosis (2015), this entire lipid architecture is a coherent downstream consequence of insulin resistance acting at the hepatic level.

The HPA Axis, Cortisol, and Sleep

Cortisol, the primary glucocorticoid output of the HPA axis, impairs insulin signaling at multiple points simultaneously. It inhibits PI3K, the kinase immediately downstream of the insulin receptor that initiates the GLUT4 translocation cascade. It directly suppresses GLUT4 expression in skeletal muscle, reducing the primary site of insulin-stimulated glucose disposal. It potentiates hepatic glucose output through upregulation of PEPCK and glucose-6-phosphatase, the rate-limiting enzymes of gluconeogenesis. As established by Rizza, Mandarino, and Gerich in the Journal of Clinical Endocrinology and Metabolism (1982) and further characterized by Andrews and Walker in Clinical Science (1999), cortisol-induced insulin resistance operates through a postreceptor defect, the insulin receptor itself may bind normally while the downstream signal fails.

Cortisol also actively remodels fat distribution. Visceral adipocytes express a higher density of glucocorticoid receptors than subcutaneous adipocytes. Chronic cortisol elevation preferentially drives fat deposition into the visceral depot. Björntorp’s analysis in Obesity Reviews (2001) established the mechanistic and epidemiological case for HPA axis hyperactivation as a primary driver of visceral obesity and its comorbidities. Cortisol also suppresses adiponectin secretion from adipocytes, removing a primary endogenous insulin sensitizer and further worsening peripheral resistance.

Sleep restriction activates the HPA axis, elevates sympathetic nervous system output, and directly impairs insulin sensitivity through the same cortisol and catecholamine pathways. Spiegel, Tasali, Leproult, and Van Cauter, reporting in Nature Reviews Endocrinology (2009), demonstrated that one week of sleep restriction to 5 hours per night reduced insulin sensitivity by approximately 25% in healthy subjects.

The Sex Hormone Dimension

Testosterone Deficiency in Men

Testosterone exerts direct effects on skeletal muscle insulin signaling through androgen receptor-mediated pathways, including upregulation of GLUT4 expression. As the primary tissue of insulin-stimulated glucose disposal, skeletal muscle mass is itself a metabolic asset and testosterone is a primary determinant of its maintenance. Testosterone deficiency drives sarcopenia (decreased muscle mass), reducing the disposal capacity of the body’s most insulin-sensitive tissue. It accelerates visceral fat accumulation, generating the very inflammatory environment that further impairs insulin signaling. Grossmann’s review in the Journal of Clinical Endocrinology and Metabolism (2011) characterized the bidirectional relationship: obesity and insulin resistance suppress testosterone, and testosterone deficiency worsens insulin resistance and metabolic risk.

Visceral adipose tissue is rich in aromatase, the enzyme that converts testosterone to estradiol. As visceral fat accumulates, aromatase activity increases, accelerating testosterone-to-estradiol conversion and driving secondary hypogonadism through estrogenic suppression of LH at the hypothalamic-pituitary axis. Inflammatory cytokines from visceral adipose tissue contribute independently to central LH suppression. Cohen’s mechanistic analysis in Medical Hypotheses (2001) characterized this as the hypogonadal-metabolic-atherogenic-disease connection — a self-sustaining loop in which each element drives the next.

The old age belly is more than an aesthetic problem for men, is the visible expression of evolving metabolic dysfunction resulting from persistent poor lifestyle habits amplified by physiological age related hormonal changes.

The Menopausal Transition in Women

Carr’s analysis in the Journal of Clinical Endocrinology and Metabolism (2003) documented what this transition produces: visceral fat accumulation that accelerates independently of total weight gain, worsening dyslipidemia following the pattern described above, and progressive insulin resistance. A woman can gain no weight during the perimenopausal years and still experience a significant shift in her metabolic risk profile, because the distribution of existing fat is changing, driven by the withdrawal of estrogen’s suppressive effects on visceral adipocyte activity.

The perimenopausal window, beginning 2 to 5 years before the final menstrual period, is the period when metabolic surveillance should intensify. It typically precedes the moment when either physician or patient is thinking in those terms.

The Pre-Menopausal Androgenic Fat Shift

Estrogen normally maintains subcutaneous fat distribution in women through lipoprotein lipase activity in gluteofemoral adipocytes and suppression of visceral adipocyte differentiation. Hyperinsulinemia disrupts this architecture through two parallel mechanisms. First, insulin stimulates ovarian theca cell androgen production through CYP17A1 upregulation, a pathway documented by Nestler et al. in the Journal of Clinical Endocrinology and Metabolism (1998) in the context of polycystic ovarian syndrome (PCOS) but operating through the same insulin receptor-mediated pathway independently of PCOS diagnostic status. Second, insulin suppresses hepatic synthesis of sex hormone-binding globulin (SHBG), as established by Plymate et al. in the Journal of Clinical Endocrinology and Metabolism (1988), raising free testosterone bioavailability independently of total testosterone levels. Standard total testosterone measurement will not detect this shift, direct SHBG measurement is required.

The result is androgenic fat redistribution toward visceral dominance in a pre-menopausal woman, without dramatic androgen elevation on standard testing, and potentially without meeting Rotterdam criteria for PCOS. The diagnostic categories of PCOS and its absence may represent points on a continuum, with hyperinsulinemia as the shared underlying driver operating at varying intensities.

SHBG is suppressed by hyperinsulinemia independently of androgen levels, and low SHBG is independently predictive of type 2 diabetes development in women. Ding et al., reporting in the New England Journal of Medicine (2009), demonstrated in prospective data that low SHBG predicted T2DM development in women with a strength of association comparable to established metabolic risk factors. It is an inexpensive, underutilized marker of insulin resistance that standard metabolic panels do not include.

Take away: abdominal fat accumulation in a pre-menopausal woman is not just an aesthetic problem but a major metabolic red flag. It warrants urgent medical evaluation, and the best laboratory test to request in such cases is SHBG levels.

In Summary

Across two pieces, a picture has been built. Insulin resistance begins as a normal biological tool. It becomes a disease through a process that is slow, largely invisible to standard screening, and self-amplifying by design.

The pancreas exhausts itself compensating. The stress system remodels fat toward the most metabolically dangerous depot. The hormonal architecture shifts against recovery in both men and women through distinct but parallel processes. The inflammatory environment generated by the disease through AGE-RAGE activation, polyol pathway oxidative stress, and cytokine output from visceral adipose fuels its own continuation. And the lipid pattern that emerges is not a parallel condition but a direct product of the same underlying resistance that medicine’s standard screening tools are failing to detect early enough to matter.

Overwhelming research evidence demonstrates this process is reversible with aggressive lifestyle modification. The highest chance of complete reversal is present at earlier stages, though remission, and more rarely reversal, is still possible at more advanced ones. Early diagnosis then becomes critical and the best tool is not a fasting glucose, or HbA1c, but an OGTT.

Part Three will show what happens to specific organ systems when the reversibility window is missed.

Found this article useful? Share your thoughts. Join the conversation below.

Educational content on The Metabolic Archives is free, because medical information should be accessible to everyone. If you find value and want to support the work, a paid subscription is available and genuinely appreciated. Visit the About Page for additional information.

Subscribe now

© 2026 The Metabolic Archives. All rights reserved.

Medicine is a sacred covenant between a person in need and a person with the knowledge and the willingness to help.

For most of human history, that relationship was the entire architecture. A patient came in, the physician examined, reasoned, and acted. Payment was direct. Accountability was personal and immediate. If the physician failed the patient, the patient knew it, and so did the community.

That system had limitations. Costs fell entirely on individuals. People without means went without care. Medicine before the mid-twentieth century had far less to offer, so that risk was lower than it would become.

The Accident That Became the Architecture

During World War II, the federal government imposed wage controls to contain wartime inflation. Employers, competing for scarce labor, found a way around it: offer health insurance as a non-wage benefit. The IRS eventually ruled these benefits tax-exempt. Congress codified the arrangement. Within two decades, employer-sponsored health insurance became the dominant model of coverage in the United States.

The structural consequence was this: the patient was no longer the payer, the employer was. And when the employer became the payer, the insurer’s client became the employer, not the patient. The insurer’s financial incentive shifted accordingly. Its obligation was to the entity writing the premium check. That entity’s primary interest was cost containment while optimal patient outcomes were sometimes secondary.

The patient, the only person whose health was actually at stake, became the party with the least power, the least information, and the least direct recourse in a transaction that existed to serve them.

The Physician as Buffer

When an insurer denied coverage for a treatment I believed was medically necessary, I was the one sitting across from the patient. I was the one who had to explain why a decision made by a reviewer I had never met, whose compensation was structured to reward denial, was going to override my clinical judgment. I was the one who absorbed the patient’s fear, confusion, and anger; not the insurer.

The physician was conscripted as the human buffer between financial decisions and their human consequences. The insurer retained the authority and externalized the moral weight. The physician retained the relationship but surrendered the authority.

Fifty Years of Bipartisan Failure

Both Republicans and Democrats controlled Congress and the White House during periods when the insurance industry consolidated power and administrative costs expanded. Multiple attempts at reform addressed symptoms while leaving the incentive structure intact, because the financial interests that benefit from that structure fund both parties.

The Affordable Care Act extended coverage to millions of Americans. While this was not a trivial achievement, it did not restructure the three-party transaction. It did not change who the insurer’s client is. Administrative costs, documented by Himmelstein and colleagues in a 2020 analysis published in the New England Journal of Medicine, consume approximately 34% of total US healthcare expenditure, the highest proportion of any developed nation measured. That figure did not improve after 2010, it got worse.

The system’s failure is bipartisan in origin and bipartisan in persistence.

The Single-Payer Premise and What I Actually Saw

The standard response to everything I have described above is a version of the same proposal: remove the private insurer, have the government pay, and the misaligned incentives disappear. The argument has surface logic, and I understand why it is appealing.

Before you decide, let me tell you a story.

I trained in Puerto Rico’s public health system in the 1980s and 1990s. What I experienced was a single payer system on American soil, serving American citizens, and I watched it operate from the inside during my clinical training there.

Puerto Rico operates under a hybrid public model: Medicaid finances a large portion of the public system, the territorial government funds the remainder. For millions of residents the public system is the only option available.

What I witnessed during my training was a system where the promise of universal access and the reality of care delivery diverged. Understaffing was common, equipment was outdated and frequently non-functional. Specialist access required long waits that in a mainland private system would have been unacceptable. Patients who could find any other option used it. Those who could not waited, sometimes for care that arrived too late to matter.

The physicians and nurses I trained alongside were skilled, committed, and working under constraints imposed by the system. The government entity responsible for funding the public health system had finite resources and unlimited demands. The rationing that resulted was the unescapable consequence of an underfunded mandate.

After Hurricane Maria in 2017, the system’s deterioration became worse. Ayala-Rodríguez and colleagues writing in the American Journal of Public Health in 2018, described the collapse of public health infrastructure.

The VA system offers a parallel. It is the closest operational analogue to single-payer healthcare serving a defined American population. The Inspector General’s audit record on VA wait times, resource allocation failures, and administrative overhead is not contested. A 2020 audit by the VA Office of Inspector General on management of consult requests found systemic failures in how the VA tracked and fulfilled clinical referrals, resulting in care delays with direct patient harm implications.

I am not arguing the current system is preferable, but that replacing private insurance administration with government simply relocates where rationing decisions are made. It adds new bureaucratic structures with their own resource consumption. It introduces political oversight as a rate-limiting step on clinical and administrative modernization.

The Conversation We Have Never Had

Every healthcare system rations care. The United States rations by ability to pay, by insurance status, by geography, by the negotiating leverage of the employer writing the premium check. Single-payer systems ration by wait time, by formulary restriction, by the political priorities of the government administering the program. There is no system in which everyone receives every intervention that might benefit them. While resources are finite, demand is infinite.

The honest conversation this country has avoided is not whether to ration. It is how, by whom, and according to what values. Until that question is engaged directly, every proposed reform is avoidance dressed as solution. We argue about the mechanism of payment and leave the underlying question untouched, because the underlying question is genuinely hard and the political cost of engaging it is high.

I practiced medicine for forty years. I entered the profession because I believed that the patient in front of me deserved my full attention, my best judgment, and my unambiguous advocacy. I spent a significant portion of those years navigating a system that made each of those things harder than they needed to be, because of a structural architecture that was never designed by intention, honestly examined, and never seriously reformed.

I do not claim to have a solution. I am one physician, with one vantage point, and the problem is larger than any single vantage point can resolve. What I have is an account of how the system works, grounded in forty years of operating inside it.

Here is Part One of this series of assays, the entry point for a conversation we all need to have, leaving feelings, ideology and party politics out. By examining the data and the facts with an open mind and full intellectual honesty we will gain an understanding of the magnitude and complexity of this problem.

What you make of it, is the part I cannot write alone.

Found this article useful? Share your thoughts. Join the conversation below.

Educational content on The Metabolic Archives is free, because medical information should be accessible to everyone. If you find value and want to support the work, a paid subscription is available and genuinely appreciated. Visit the About Page for additional information.

Subscribe now

© 2026 The Metabolic Archives. All rights reserved.

A quick note before you read: This piece is the densest in this series. It covers molecular biology, evolutionary biology, endocrinology, and metabolic pathophysiology because those layers are necessary to understand everything that follows. Each mechanism is presented in precise scientific terms, and expanded in plain language where needed. The narrative reflects the intricacy of a very complex biological system.

Insulin is one of the most ancient biological signaling molecules ever identified, present in organisms that predate vertebrates by hundreds of millions of years. Researchers have found insulin-related peptides in mollusks and insects, in organisms with no pancreas and no blood glucose regulation in any recognizable sense (Le Roith et al., PNAS, 1980). The system you carry is not new. What is new is the environment you are running it in.

That mismatch is where this story begins.

An Ancient System in a Novel Environment

This signaling machinery evolved for a world of intermittent nutrient availability; feast and famine. The system’s design parameters were never three meals a day plus snacks, or foods engineered for maximal palatability and minimal satiation.

This system stores energy aggressively during abundance. It preserves critical fuel reserves during scarcity. It coordinates multiple organs simultaneously to accomplish this. When you understand what it was designed to do, insulin resistance stops looking like a random malfunction. It starts looking like a predictable consequence of running an ancient system under conditions it was never designed for.

How Insulin Is Made and Released

When you eat a meal containing carbohydrate, glucose enters your bloodstream and reaches the beta cells of the pancreatic islets. Those cells contain a specialized glucose transport protein called GLUT2, which allows glucose to enter the cell in direct proportion to its concentration in the blood. Once inside, an enzyme called glucokinase phosphorylates the glucose, initiating its metabolism. As glucose is metabolized, ATP (the main cellular fuel) production rises. That rising ATP-to-ADP ratio closes ATP-sensitive potassium channels in the cell membrane, which depolarizes the membrane, opens voltage-gated calcium channels, and triggers the exocytosis of insulin-containing vesicles into the bloodstream (Matschinsky, Journal of Clinical Investigation, 1990).

In simpler terms, as glucose enter the beta cells it stimulates a proportional release of insulin back into the blood stream. The system modulates its output continuously based on real-time glucose concentration.

Protein also stimulates insulin secretion, though the response is roughly 50 to 70 percent of what an equivalent carbohydrate load would produce, varying by protein source. Protein also stimulates glucagon secretion from the alpha cells of the pancreatic islets, which partially counteracts the glucose lowering effect of insulin and contributes to protein’s superior satiety characteristics.

What Insulin Actually Does

Skeletal muscle is the dominant site of postprandial glucose disposal. Under insulin stimulation, skeletal muscle takes up and stores approximately 70 to 80 percent of the glucose consumed in a meal (DeFronzo et al., Diabetes, 1981). This figure comes from landmark euglycemic clamp studies and remains the most thoroughly established number in postprandial glucose metabolism.

The liver suppresses its own endogenous glucose output in response to insulin. Between meals and overnight, the liver produces glucose through glycogenolysis, break down of hepatic glucose stores, and gluconeogenesis, metabolize new glucose mostly from fatty acids, to maintain blood glucose levels. After a meal, insulin signals the liver to stop. Failure of this suppression is a primary driver of fasting hyperglycemia in type 2 diabetes.

Adipose tissue responds to insulin by inhibiting lipolysis, the breakdown of stored triglycerides into free fatty acids, and promotes the storage of incoming dietary fat. This prevents the free fatty acid flooding that, as you will see, plays a central role in the pathological cascade.

Glucagon, cortisol, and epinephrine all oppose insulin’s effects through distinct mechanisms, raising blood glucose when it drops. The result is a finely tuned thermostat, maintaining glucose within a narrow physiological range regardless of whether you have just eaten or have been fasting for twelve hours.

The Molecular Relay Inside the Cell

Think of glucose entry into a cell as gaining access to a high-security vault. The vault requires four guards to approve entry in sequence. Any of the steps in the sequence fails, the vault stays locked.

Here is what the four steps in the process are.

Step One: insulin in the bloodstream binds to the insulin receptor on the cell surface. The receptor is a tyrosine kinase, and activates by phosphorylating itself on tyrosine residues.

Step Two: the activated insulin receptor recruits insulin receptor substrate-1 (IRS-1) and phosphorylates it, also on tyrosine residues. This tyrosine phosphorylation is the critical activating event for the entire cascade. It creates docking sites for the next step, and is the point where the pathological lesion is introduced.

Step Three: phosphoinositide 3-kinase (PI3K) docks onto the tyrosine-phosphorylated IRS-1 and generates a lipid second messenger called PIP3. PIP3 diffuses along the inner face of the cell membrane and recruits Akt

Step Four: protein kinase B (Akt) is recruited to the membrane by PIP3 and activated there by two upstream kinases, PDK1 and mTORC2. Once active, Akt phosphorylates a protein called AS160, which releases GLUT4-containing vesicles inside the cell. Those vesicles migrate to the plasma membrane, GLUT4 transporters embed into the surface and glucose enters.

Every step in that cascade is dependent on the one before it. Failure of any step GLUT4 stays inside the cell, and glucose cannot enter despite normal or even elevated insulin concentrations in the blood.

Insulin Sensitivity Is Not a Fixed Trait

Insulin sensitivity is not a fixed biological characteristic. It is continuously variable, moving up and down in response to conditions that are largely within your influence.

1. A single week of sleep restriction to five hours per night reduces insulin sensitivity by approximately 25 percent in otherwise healthy subjects (Spiegel et al., Nature Reviews Endocrinology, 2009).

2. An episode of moderate-intensity exercise improves insulin sensitivity through an insulin-independent pathway involving AMP-activated protein kinase (AMPK), which drives GLUT4 translocation directly without requiring insulin (Richter and Hargreaves, Physiological Reviews, 2013).

3. Cortisol, released during psychological or physiological stress, suppresses insulin sensitivity within hours through mechanisms involving hepatic glucose production and peripheral receptor resistance.

Insulin Resistance as a Normal Biological Tool

Insulin resistance is a normal physiological process useful in specific biological contexts where redirecting fuel is necessary.

Pregnancy is a good example: beginning in the second trimester, human placental lactogen (hPL) drives a progressive state of peripheral insulin resistance in the mother. That reduces maternal glucose uptake and redirects glucose across the placenta to the developing fetus, which has an absolute requirement for glucose as its primary fuel (Barbour et al., Diabetes Care, 2007).

Similar mechanisms operate during the luteal phase of the menstrual cycle, puberty, and acute systemic illness or any context in which the body’s fuel priorities need to shift.

Where the Molecular Machinery Breaks Down

Under normal signaling, IRS-1 is phosphorylated on tyrosine residues, which activates the downstream cascade. Under pathological conditions, IRS-1 is instead phosphorylated on serine residues. Serine phosphorylation of IRS-1 acts as an inhibitory modification, blocking its interaction with PI3K and effectively stopping the cascade (White, American Journal of Physiology, 2002).

JNK (c-Jun N-terminal kinase) is activated by inflammatory cytokines and oxidative stress. IKKbeta is activated by the same cytokine milieu and by lipopolysaccharide (LPS) acting through Toll-like receptor 4 (TLR4). PKCtheta in skeletal muscle and PKCepsilon in the liver are activated by intracellular accumulation of diacylglycerols (DAG). All three kinases converge on the same target: IRS-1 serine residues.

A secondary lesion operates downstream. Ceramide accumulation, driven by saturated fatty acid excess and inflammatory signaling, directly inhibits Akt. (Summers, Progress in Lipid Research, 2006).

Molecular Pathways Driving Insulin Resistance

Ectopic lipid and the DAG-PKC axis. When fat storage capacity in subcutaneous adipose tissue is exceeded, lipid accumulates in tissues not designed for it: liver, skeletal muscle, and pancreas. This ectopic fat generates intracellular DAG, which activates PKCepsilon in the liver and PKCtheta in skeletal muscle, driving IRS-1 serine phosphorylation (Shulman, New England Journal of Medicine, 2014; Samuel et al., Journal of Biological Chemistry, 2004). This is the best-characterized mechanism of insulin resistance, with strong replicated evidence from both human and animal studies.

Adipose tissue dysfunction and inflammatory cytokine signaling. As adipose tissue expands beyond its functional capacity, it recruits macrophages, which form characteristic crown-like structures around dying adipocytes. These macrophages produce TNF-alpha and IL-6, inflammatory cytokines that activate JNK and IKKbeta in multiple tissues, driving IRS-1 serine phosphorylation remotely (Weisberg et al., Journal of Clinical Investigation, 2003; Hotamisligil et al., Science, 1993). This pathway is well established in both human and animal models.

Gut dysbiosis and metabolic endotoxemia. Disruption of the intestinal microbiome and increased intestinal permeability allows bacterial lipopolysaccharide (LPS) to translocate into portal and systemic circulation. LPS activates TLR4, which drives IKKbeta-mediated IRS-1 serine phosphorylation in liver and adipose tissue (Cani et al., Diabetes, 2007). The mechanistic case is compelling, and elevated plasma LPS in people with metabolic syndrome is replicated consistently. The causal relation in humans remains emerging evidence rather than established fact. The animal data are strong; the human interventional data is accumulating.

ER stress and the unfolded protein response. Nutrient excess and lipid overload trigger endoplasmic reticulum stress in metabolically active cells, activating the IRE1alpha-JNK pathway and driving IRS-1 serine phosphorylation. This mechanism is well characterized in animal models and human adipose and liver tissue, though the precise contribution relative to other pathways in humans is not fully quantified.

Mitochondrial dysfunction and reactive oxygen species. Impaired mitochondrial function increases reactive oxygen species (ROS) production, which activates JNK and other stress kinases driving the serine phosphorylation lesion. The relationship is bidirectional: insulin resistance impairs mitochondrial function, and mitochondrial dysfunction worsens insulin resistance. The causal direction has not been fully established in humans, and this pathway should be understood as a reinforcing loop rather than a clear initiating driver.

Hyperinsulinemia as a feed-forward accelerant. Chronically elevated insulin concentrations, whether driven by peripheral resistance or by continuous high-carbohydrate feeding, downregulate insulin receptor expression and activate S6K1, which independently phosphorylates IRS-1 on serine residues. This creates a self-amplifying loop: compensatory hyperinsulinemia worsens the very resistance that drove it. This is a strongly supported hypothesis with coherent mechanistic grounding, though establishing it as a primary initiating driver rather than a secondary accelerant remains an area of active investigation.

The Personal Fat Threshold

One important explanatory frameworks for understanding why metabolic risk varies so dramatically between individuals is the personal fat threshold concept, developed primarily through the work of Roy Taylor and the Newcastle group.

Every individual has a genetically and developmentally determined capacity for safe fat storage in subcutaneous adipose tissue. When that capacity is not exceeded, excess calories are stored without metabolic consequence. When it is exceeded, fat spills into ectopic sites: liver, skeletal muscle, pancreas, and pericardium. It is this ectopic deposition, not fat mass per se, that initiates the metabolic cascade.

The metabolically obese normal-weight individual carries a high total fat mass in ectopic depots because their subcutaneous storage capacity was exceeded at a relatively low absolute fat mass. The metabolically healthy obese individual carries a high absolute fat mass almost entirely in subcutaneous depots, because their storage capacity is large enough to accommodate it without ectopic spillover.

The personal fat threshold is not currently measurable with clinical tools. It cannot be determined for any individual patient. It is presented here as a strongly supported theoretical framework, not an operational clinical variable.

Research using carbon-14 dating of adipocyte DNA established that total adipocyte number stabilizes in early adulthood and does not change materially with subsequent weight gain or loss (Spalding et al., Nature, 2008). What changes is cell size. Adipocyte number is established partly during childhood, and childhood obesity drives hyperplastic adipose expansion, increasing total cell number permanently. This has direct implications for the difficulty of weight regulation in adults who were obese as children, and it has direct implications for why pediatric metabolic health matters in ways that extend decades into adulthood.

Visceral Versus Subcutaneous Fat

Not all adipose tissue carries the same metabolic risk. Visceral adipocytes express higher densities of glucocorticoid and androgen receptors than subcutaneous adipocytes, making them more responsive to cortisol-driven lipolysis. They are intrinsically more lipolytically active and carry greater baseline inflammatory tone. Anatomically they drain directly into the portal circulation via the portal vein, delivering their free fatty acids and inflammatory mediators directly to the liver before they reach systemic circulation. (Despres and Lemieux, Nature, 2006).

Subcutaneous fat, particularly in gluteofemoral depots, behaves differently. It is metabolically less active, less inflammatory, and anatomically positioned to drain into systemic rather than portal circulation. Research suggests that gluteofemoral fat functions as an active metabolic buffer, sequestering lipid that would otherwise enter ectopic depots. This partially explains the protective metabolic profile associated with gynoid fat distribution (pear-shape).

In women, the menopause-associated redistribution of fat from subcutaneous to visceral depots, driven by declining estrogen and relative androgenic predominance, represents a significant and often underappreciated metabolic inflection point. This androgenic fat shift and its mechanisms will be developed fully in Part Two.

Summary

By now you have a better understanding of what insulin is, what it evolved to do, how its intracellular signal propagates through a sequential molecular relay, and precisely where that relay fails in pathological insulin resistance. You understand that insulin resistance is a normal physiological tool that becomes pathological only when it cannot resolve. You understand that multiple biological pathways converge simultaneously on a single molecular lesion. You understand that individual variation in fat storage capacity determines metabolic risk independently of absolute fat mass, and that visceral and subcutaneous adipose tissue are fundamentally different in their metabolic consequences.

Part Two will show what happens when the mechanism cannot turn off: the self-sustaining loops that convert compensated insulin resistance into progressive metabolic disease, the organ-specific consequences, and the inflection points at which the clinical trajectory changes.

Found this article useful? Share your thoughts. Join the conversation below.

Educational content on The Metabolic Archives is free, because medical information should be accessible to everyone. If you find value and want to support the work, a paid subscription is available and genuinely appreciated. Visit the About Page for additional information.

Subscribe now

© 2026 The Metabolic Archives. All rights reserved.

On February 27, 2026, HHS Secretary Robert F. Kennedy Jr. announced that approximately 14 of the 19 injectable peptide compounds the FDA had restricted from compounding pharmacies in 2023 are expected to be reclassified moving from the restricted Category 2 list back to Category 1, which means licensed compounding pharmacies could legally prepare and dispense them again under physician prescription. As of this writing, the FDA has not yet published its formal updated list.

Before these compounds reach your pharmacy, you need to understand what the evidence actually shows. Not what the wellness industry says it shows.

A Peptide Is Not a Medicine

Your body produces thousands of peptides that regulate hunger, sleep, immune response, tissue repair, stress, and dozens of other functions.

When the wellness industry markets “peptide therapy,” it is borrowing the credibility of that entire category including, most deliberately, the credibility of two medicines that genuinely transformed metabolic care: insulin, which has been in clinical use for over a century, and semaglutide (Ozempic, Wegovy), which has produced some of the most dramatic obesity and cardiovascular outcomes data in modern medicine.

What made insulin and semaglutide medicines was not their chemistry. For semaglutide, that meant identifying the GLP-1 receptor target, characterizing the pharmacokinetics in humans, running Phase I trials in healthy volunteers to establish safety, then Phase II trials to establish dose-response relationships, then Phase III trials enrolling tens of thousands of patients across multiple independent research programs, measuring hard clinical endpoints, weight, cardiovascular events, mortality, and submitting all of that to independent regulatory review. The SUSTAIN trial program for glycemic control and the SELECT trial for cardiovascular outcomes enrolled over 17,000 patients combined. Independent researchers replicated the findings. The FDA reviewed the complete data package.

The False Equivalence at the Center of the Marketing

The argument made by the wellness peptide industry is this: these compounds are peptides, peptides like semaglutide work, therefore these compounds may work similarly and the regulatory barriers are excessive.

Membership in a molecular category confers nothing about safety or efficacy. The evidentiary hierarchy, from cell culture to animal models to Phase I human safety trials to Phase II to Phase III, exists because history is filled with compounds that healed animals and failed or harmed people. Thalidomide was highly effective in animal models, yet it led to severe birth defects in humans.

Take BPC-157, arguably the most widely marketed of these compounds. According to a 2025 systematic review in HSS Journal, a reputable orthopedic surgery publication, the reviewers examined 544 articles published from 1993 through 2024. They identified 35 preclinical studies and one clinical study: a 12-patient retrospective pain series. The review’s explicit conclusion was that no clinical safety data exists.

Reclassification to Category 1 only changes the legal pathway for access. BPC-157 still has only a handful of published human studies with fewer than 30 total subjects. TB-500 has no completed human randomized controlled trials.

The Seven Compounds, What the Evidence Actually Shows

BPC-157 is a synthetic fragment of a protein found in gastric juice. It is marketed for tissue healing, gut repair, and injury recovery. The biological mechanism being proposed, promotion of new blood vessel growth, is real and has been characterized in animal studies. But that same mechanism, involving upregulation of VEGFR2 and downstream vascular signaling pathways, is precisely what oncologists target with anti-angiogenic drugs to starve tumors of their blood supply. In a person with an occult or active malignancy, we do not know what BPC-157 does.

TB-500 is a synthetic fragment of thymosin beta-4, marketed for muscle recovery and injury repair. Phase I human safety data does exist for the intact thymosin beta-4 molecule, administered intravenously under pharmaceutical-grade conditions to healthy volunteers in controlled trials. (Ruff et al., Annals of the New York Academy of Sciences, 2010; Wang et al., Journal of Cellular and Molecular Medicine, 2021). The fragment being sold as TB-500 is not the studied molecule. Safety data on a structurally related compound is not safety data for this product.

PT-141 (bremelanotide) an approved version of this compound exists; Vyleesi, a 1.75 mg subcutaneous autoinjector, underwent controlled randomized trials in premenopausal women with acquired generalized hypoactive sexual desire disorder. The trials documented transient blood pressure increases peaking around 12 minutes post-injection, with documented exclusion criteria for cardiovascular risk. Postmenopausal women and men were not part of the studied population. Compounded intranasal bremelanotide formulations are not Vyleesi. They deliver an unknown dose via an unstudied delivery route to an unstudied population, including people with cardiovascular conditions who were specifically excluded from the trials that established the compound’s risk profile.

Selank and Semax are synthetic neuropeptides developed in Russia, where the majority of human research on these compounds originates. A 2020 neuroimaging study at a Russian institution enrolled 52 healthy participants and documented measurable effects on amygdala functional connectivity (Panikratova et al., Doklady Biological Sciences, 2020). That is the largest human study identified for either compound. No independent replication exists. Changes in functional connectivity do not establish clinical efficacy. These compounds have more human data than BPC-157 or TB-500, which is not the same as having adequate human data.

Epithalon is marketed primarily on anti-aging and longevity claims, specifically around telomere lengthening. Telomere shortening is associated with aging, but the biology is not the simple linear equation the marketing implies; correlation between telomere length and chronological age in a 2023 meta-analysis of 743,019 individuals was -0.19, statistically significant but modest (Ye et al., Ageing Research Reviews, 2023). More critically, in cancer biology, telomere lengthening is specifically the mechanism by which malignant cells escape the natural limit on how many times a cell can divide (replicative senescence). A 2025 peer-reviewed study in Biogerontology confirmed that Epithalon activates telomere lengthening in breast cancer cell lines through the ALT mechanism (Al-dulaimi et al., Biogerontology, 2025).

The Manufacturing Problem No One Is Talking About

Even if the evidence for any of these compounds were stronger than it is, a separate and independent problem remains: you are not receiving a pharmaceutical-grade product.

FDA approval of a drug covers far more than the molecule. It covers the dose, the formulation, the manufacturing process, the delivery system, and the studied population. A compounding pharmacy can legally prepare a compound but cannot replicate the level of pharmaceutical manufacturing oversight that accompanied the clinical trials establishing whatever limited evidence exists.

A 2024 analysis of gray-market peptide products found significant variability in actual peptide content versus label claims, contamination with bacterial endotoxins, and in some cases, entirely wrong compounds in the vial.

Industry sources and proponents of these compounds have themselves acknowledged that much of the active pharmaceutical ingredient used in compounding originates from Chinese chemical manufacturers operating outside Good Manufacturing Practice (GMP) oversight. The quality depends entirely on a chain of custody that no regulatory body is monitoring.

Several of these compounds are sold in nasal spray form, Semax, Selank, and PT-141 variants appear most commonly in this format. The nasal mucosa presents three overlapping barriers to peptide absorption: enzymatic degradation by peptidases and proteases present in nasal secretions, tight junction barriers in the mucosal epithelium, and mucociliary clearance that physically removes deposited material before it can be absorbed.

Novo Nordisk, Pfizer, and other major pharmaceutical companies with dedicated science divisions invested decades of resources and serious scientific effort in intranasal insulin delivery, but they could not make it work reliably. Studies found intranasal doses requiring approximately 20 times higher than subcutaneous doses, with bioavailability of 16–20% at best and high inter-individual variability (Hilsted et al., Diabetologia, 1995; Leary et al., Diabetes Technology and Therapeutics, 2006). A 2024 adaptive dose-escalation study administered up to 1,000 units intranasally and still found idiosyncratic absorption with two hypoglycemic episodes at 600 units, unpredictable even at extreme doses (Schmitzberger et al., Clinical and Translational Science, 2024).

No intranasal insulin formulation to date has received regulatory approval for metabolic use. A compounding pharmacy dissolving a peptide in saline and filling a nasal spray bottle has not solved what industrial pharmaceutical science could not.

How to Think About This

The February 2026 announcement suggests that some of these compounds will soon be accessible through legitimate pharmacy channels rather than gray-market chemical suppliers. That is an improvement in quality control for people who are going to use them regardless of what the evidence shows.

If a wellness practitioner or compounding pharmacy is currently offering you these compounds, here are the questions worth asking before you agree:

• What is the specific mechanism of action, and what human data supports it? Not animal data, human data from Phase I or II trials, with sample sizes and published in peer-reviewed journal. If the practitioner cannot name specific studies with human subjects, you have your answer.

• What adverse effects were documented in the studied population, and am I in a group that was excluded from those studies? PT-141’s cardiovascular effects in people with cardiac risk factors are undefined. BPC-157’s behavior in someone with occult malignancy is unknown.

• Where was the active ingredient manufactured, and what quality certification applies to that facility? GMP certification from an FDA-recognized facility is the minimum standard. “Research use only” material is not manufactured to human-use quality standards.

• If something goes wrong, who is monitoring for it, who do I report it to, and what accountability structure exists? The answer under the current system is: essentially none.

The evidence does not currently support use of most of these compounds outside of properly designed clinical trials. Several of these compounds present interesting biological hypotheses, and some may eventually earn clinical validation through the pathway that semaglutide and insulin traveled. But the possibility of future evidence is not the same as current evidence.

If you are being offered these compounds today, you are not participating in cutting-edge medicine. You are paying to be an unmonitored subject in an uncontrolled experiment with no follow-up and no data collection.

Found this article useful? Share your thoughts. Join the conversation below.

Educational content on The Metabolic Archives is free, because medical information should be accessible to everyone. If you find value and want to support the work, a paid subscription is available and genuinely appreciated. Visit the About Page for additional information.

Subscribe now

© 2026 The Metabolic Archives. All rights reserved.

You have probably experienced this more than once. January arrives, resolve is high. You commit to a specific diet plan. The first two weeks go well. By week four, something gives. By week eight, the plan is gone and the old habits are back.

The Real Reason Diets Don’t Stick

A 2020 digital epidemiological study published in PLOS ONE tracked real-world adherence to dietary plans using search and behavioral data across millions of users (Towers et al., PLOS ONE, 2020). Every major diet showed the same pattern: a sharp January spike, followed by rapid decline. Average compliance across popular dietary plans lasted approximately three to five weeks. In structured clinical intervention programs, where participants receive professional guidance, regular check-ins, and motivational support, dropout rates still exceed 40% within the first twelve months (Frontiers in Nutrition, 2022). Even in rigorous randomized controlled trials, participants tend to revert to prior eating habits once the study ends (McMahon et al., Nutrients, 2022).

Rigid externally designed meal plans built around unfamiliar foods require a complete behavioral overhaul layered on top of an already complex life. Most people cannot sustain that alongside work, family, budget constraints, and cultural food traditions.

The more productive question is not which diet should I follow this time? It is: what do these diets actually do, and can I do that with the food I already eat?

Three Diets, Three Principles

The three dietary systems below were extensively studied. Each works through a specific identifiable mechanism. And each mechanism can be applied to nearly any food culture, any budget, and any kitchen without wholesale adoption of the full dietary system.

The Mediterranean Diet, Fat Quality Principle

The Mediterranean dietary pattern emerged from epidemiological observations in the 1950s and 1960s noting that populations around the Mediterranean basin had substantially lower rates of cardiovascular disease than northern European and American populations despite diets that were high in fat. Decades of research have since traced much of that benefit to the type of fat consumed, not the amount.

Extra-virgin olive oil (EVOO) is the cornerstone. It is rich in oleic acid, a monounsaturated fatty acid, and contains bioactive polyphenols, including hydroxytyrosol and oleocanthal, that exert antioxidant, anti-inflammatory, vasodilatory, and lipid-modulating effects in the body (Nocella et al., Biomolecules, 2025). Multiple clinical and prospective cohort studies confirm associations between EVOO consumption and reductions in major modifiable cardiovascular risk factors, including hypertension, dyslipidemia, and markers of systemic inflammation (Covas et al., Cardiology in Review, 2024). The PREDIMED trial, a landmark Spanish randomized controlled trial, demonstrated a 30% reduction in major cardiovascular events among participants assigned to a Mediterranean diet supplemented with extra-virgin olive oil compared to a low-fat control diet (Estruch et al., NEJM, 2013). Large prospective cohort data from US populations confirm inverse associations between olive oil consumption and cardiovascular mortality (Guasch-Ferré et al., JACC, 2022).

The transferable principle: replace lower-quality fats with extra-virgin olive oil where possible, and increase whole plant foods.

Practical note: EVOO has a smoke point of approximately 375–405°F (190–207°C), which makes it well-suited for dressings, low-to-medium heat cooking, and finishing dishes, but unsuitable for high-heat applications like hard searing or frying. For those, avocado oil is a practical alternative, it has a comparable monounsaturated fat profile and a smoke point of approximately 480–520°F (250–270°C). Evidence on avocado oil as an independent cardiovascular intervention is still emerging.

A note on alcohol: the traditional Mediterranean dietary pattern includes moderate red wine consumption. The 2026 AHA Dietary Guidance and the 2025 AHA/ACC Hypertension Guidelines explicitly recommend reducing or avoiding alcohol for cardiovascular health.

The DASH Diet, Sodium-Potassium Balance Principle

DASH, Dietary Approaches to Stop Hypertension, was developed in the 1990s in response to the growing burden of high blood pressure in the US population. It is commonly described as a low-sodium diet but that description is incomplete.

DASH works primarily by flooding the diet with potassium-rich whole foods (i.e., vegetables, fruits, and legumes) that actively counteract the blood-pressure-raising effects of sodium through distinct physiological mechanisms. Higher potassium intake drives sodium excretion through the kidneys and relaxes arterial walls. The INTERMAP study, a large international collaborative analysis, found that higher potassium intake from plant foods is strongly associated with lower blood pressure independent of sodium intake (INTERMAP Cooperative Research Group, American Journal of Hypertension, 2022). A systematic review and meta-analysis found that higher potassium intake reduces systolic blood pressure by approximately 3.5 mmHg and diastolic blood pressure by approximately 2 mmHg (referenced in IJVNR sodium review, 2025). The DASH dietary pattern itself, targeting a potassium intake of approximately 4.7g per day through vegetables, fruits, and legumes, demonstrated blood pressure reductions of 11 mmHg systolic in hypertensive patients and 3 mmHg in normotensive individuals (PMC10759559, 2024).

The 2026 AHA Dietary Guidelines, published in Circulation, explicitly endorses a combined sodium-reduction and potassium-increase approach for hypertension prevention and control, achievable through a diet high in vegetables and fruits (AHA, Circulation, 2026).

The transferable principle: add more potassium-rich whole foods such as beans, lentils, leafy greens, tomatoes, potatoes, bananas, citrus.

The Volumetric Diet, Meal Sequence and Satiety Principle

Volumetric eating, developed by Barbara Rolls at Penn State, is built on the concept of energy density: the number of calories per gram of food. Foods with high water and fiber content provide substantial volume and physical fullness with relatively few calories. Foods with low water content (i.e., processed snacks, refined grains, fried foods) deliver a large caloric load in a small physical package.

A randomized crossover study found that consuming a broth-based soup before a meal reduced total meal energy intake by approximately 20% (about 134 calories) compared to no soup (Rolls et al., Appetite, 2007). Pre-meal salad consumption reduced meal energy intake by 7–12% depending on portion size, with larger lower-energy-dense salads producing the greatest reduction (Rolls et al., Journal of the American Dietetic Association, 2004). The mechanism involves gastric distension alongside early satiety signals that engage before the calorie-dense portion of the meal is consumed. A 2022 meta-analysis of 38 randomized controlled trials found that lowering dietary energy density reduced energy intake by an average of 223 kcal per day (Klos et al., AJCN, 2022).

This is also the scientific basis for the traditional European multi-course meal sequence, salad and/or soup before the main course, which weren’t understood when the tradition developed.

The transferable principle: begin your meal with the lowest-calorie-density food on the table, a salad or a bowl of broth-based soup. You will eat less of everything that follows.

Putting It Together

Consider someone who does not follow any specific diet, has no interest in adopting one, and would leave immediately if handed a meal plan. They like what they like. Here is what applying these three principles looks like for them.

They switch to olive oil for everyday cooking and salad dressings. For high-heat cooking, they add avocado oil to the pantry. Two oils. No further changes to how they cook. (Mediterranean; fat quality)

They add a salad before dinner a few nights a week dressed with a simple olive oil vinaigrette instead of Ranch dressing. (Mediterranean + Volumetric; fat quality and pre-meal volume)

They already like beans. Learning that beans is a potassium-rich, fiber-dense, and metabolically beneficial food, they make them more often and replace one or two red meat portions per week. (Mediterranean + DASH; plant foods, high potassium intake, reduced saturated fat)

They start reading sodium content on nutrition labels to identify items in their routine shopping list with the most sodium load, and choosing a lower-sodium alternative when available. (DASH; sodium awareness without obsessive tracking)

They like fruit. They buy more of the varieties they already enjoy and keep them visible. Fruit becomes a more common desert replacing a few portions of ice cream per week. (Mediterranean + DASH; higher fruit intake)

They simply applied five principles to food they already knew and liked. Each change fits their existing life because it was built around it. None of the changes required eliminating anything they enjoy.

Deprivation is one of the primary drivers of dietary abandonment. A strategy that reduces ice cream by making fruit more present and convenient is behaviorally more durable than elimination.

A Point Worth Noting

Ultra-processed foods, products formulated from industrial ingredients rather than whole foods, are consistently associated with higher intakes of saturated fat, added sugar, and sodium, alongside lower intakes of fiber and micronutrients (PMC12734455, 2025). The 2025–2030 US Dietary Guidelines, and the AHA in January 2026, explicitly emphasize limiting consumption of highly processed foods, added sugars, refined grains, and saturated fats (AHA Newsroom, January 2026).

Reducing ultra-processed food consumption addresses all three of the dietary targets that Mediterranean, DASH, and Volumetric eating approach from different angles simultaneously. It is the single most accessible starting point for most people.

A Single Change at a Time

Look at the principles covered in this article: fat quality, potassium over sodium, higher fruit and vegetable intake, pre-meal volume. Identify one change that fits your life today, small enough that you can adopt with minimal inconvenience. If it holds, add one more next month. That is twelve meaningful dietary changes in a year. Not a diet, a different relationship with food built using what you already eat.

Multiple small and sustainable healthy changes in your diet will be more beneficial than abruptly adopting a new dietary system you are unlikely to sustain long term. Go ahead, start today.

The diets covered in this article are not prescriptions, they are maps. You do not need to follow any of them completely. You need to understand what makes each one work, take what fits your life and make it work within your existing food preferences.

Found this article useful? Share your thoughts. Join the conversation below.

Educational content on The Metabolic Archives is free, because medical information should be accessible to everyone. If you find value in it and want to support the work, a paid subscription is available and genuinely appreciated. Visit the About Page for additional information.

Subscribe now

© 2026 The Metabolic Archives. All rights reserved.

The GLP-1 You’re Prescribing May Not Work for One in Ten of Your Patients

A decade-long international collaboration published April 10 in Genome Medicine has identified a set of genetic variants — carried by roughly 10% of the general population — that appear to blunt the blood-glucose-lowering effect of GLP-1 receptor agonists in patients with type 2 diabetes. Researchers from Stanford, ETH Zurich, Adelaide University, and the University of Parma combined human clinical trial data, animal experiments, and pharmacogenomic analysis to characterize what they’re calling “GLP-1 resistance”: a state in which circulating GLP-1 hormone levels are elevated but biologically less effective. In clinical trial data, patients carrying these variants failed to lower their HbA1c as effectively as non-carriers after six months on GLP-1 drugs. Senior author Anna Gloyn of Stanford Medicine framed this as a precision medicine opportunity — knowing a patient’s genotype ahead of time could prevent months of ineffective therapy and speed time to the right drug. The critical caveat: the study focused specifically on glycemic outcomes, not weight loss. Whether these variants similarly blunt weight loss at the higher doses used in obesity treatment remains an open and clinically important question. For now, prescribers can’t yet order a clinically validated genotype panel before initiating a GLP-1.

🔗 Stanford Medicine News | Genome Medicine (original study)

Generic Dapagliflozin Is Here — and the Access Implications Are Real

On April 7, the FDA approved the first true generic versions of dapagliflozin (brand name Farxiga), clearing multiple manufacturers to bring lower-cost SGLT2 inhibitor tablets to the US market. The approvals cover two indications: glycemic control as an adjunct to diet and exercise in adults with type 2 diabetes, and reduction of heart failure hospitalization risk in patients with T2D who have established cardiovascular disease or multiple cardiovascular risk factors. Dapagliflozin has robust outcome trial data behind it — it’s one of the best-evidenced drugs in metabolic medicine for cardiorenal protection — and cost has been a meaningful barrier. Notably, the generic label currently excludes several of the branded product’s approved indications, including the chronic kidney disease indication, which clinicians should verify before switching patients who are prescribed dapagliflozin specifically for CKD.

🔗 FDA Drug Alert | Pharmaceutical Technology

GLP-1s and Bariatric Surgery Produce Comparable Body Composition Changes — Including Lean Mass Loss

A retrospective study from Vanderbilt University Medical Center, published in JAMA Network Open, compared body composition changes over 24 months in 1,257 patients who underwent bariatric surgery and 1,809 patients treated with semaglutide or tirzepatide. The main finding: both interventions produced substantial fat mass reduction alongside a smaller but consistent decline in fat-free mass — including lean muscle. The pattern was similar regardless of whether patients had surgery or took a GLP-1 drug. This matters because lean mass is independently protective against all-cause mortality in patients with obesity. The study used bioelectrical impedance analysis rather than DEXA, which introduces measurement variability and limits precision — a meaningful limitation given that the degree of muscle loss is exactly what’s at issue. The authors appropriately flag the need for more rigorous real-world body composition data. For clinicians, this study doesn’t change prescribing decisions: resistance training and adequate protein intake during treatment are part of the treatment plan.

🔗 ScienceDaily / Vanderbilt | JAMA Network Open (DOI)

Lilly’s Oral GLP-1 Pill Foundayo Gets FDA Green Light — Convenience, Not Efficacy, Is the Story

On April 1, the FDA approved Eli Lilly’s orforglipron (brand name Foundayo), making it the second oral GLP-1 receptor agonist approved for obesity management in the US, following Novo Nordisk’s oral semaglutide in December 2025. Foundayo is notable for being a small-molecule, non-peptide GLP-1 agonist — meaning it can be taken at any time of day without the food and water restrictions that complicate oral semaglutide dosing. It’s also among the first drugs approved under the FDA’s new Commissioner’s National Priority Voucher program, which is designed to accelerate access for high-priority treatments. Phase 3 data showed orforglipron lowers blood glucose at least comparably to oral semaglutide. Industry analysts project significant market share, with Clarivate estimating over $11 billion in G7 obesity market sales by 2031. The clinical caveat is that orforglipron’s long-term cardiovascular outcome data is not yet available as the drug competes in a market where semaglutide has SELECT trial cardiovascular data behind it. Prescribers should not assume cardiovascular benefit class equivalence until those trials report.

🔗 Medical News Today | DCAT Value Chain Insights

AI-Identified Peptide “BRP” Mimics GLP-1 Weight Loss in Animals — Without the Side Effects

Stanford Medicine researchers published a study in Nature describing a naturally occurring peptide called BRP that reduced appetite and body weight in animal models while appearing to avoid several common GLP-1 side effects — specifically nausea, constipation, and lean mass loss. BRP was identified using an AI screening approach that sorted through a large library of prohormones — inactive precursor molecules that can be cleaved into functional peptide hormones. Unlike semaglutide, which acts on GLP-1 receptors distributed broadly across the gut, pancreas, and brain, BRP appears to act specifically in the hypothalamus, potentially explaining the more targeted appetite effect and reduced peripheral side effects in rodents. Senior author Katrin Svensson has also co-founded a company planning human clinical trials. BRP is genuinely interesting basic science; whether it translates is a question that clinical trials — likely years away from answering — will have to resolve. Watch this space, but don’t get ahead of the evidence.

🔗 ScienceDaily / Stanford Medicine

This newsletter summarizes recent research and news for informational and educational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional for personal medical decisions.

Subscribe at The Metabolic Archives. Forward to a colleague who should be reading this.

The weight loss industry generates between $20 and $33 billion annually in the United States. It has done so for decades, yet obesity rates have climbed throughout. If any of this were working at the population level, the numbers would look different.

That gap between what the industry spends and what it produces is not an accident. The industry sells solutions that do not produce lasting results to people who will blame themselves when they fail, and return to try again. The science tells a different story one that starts not with the diet, but with the biology underneath it.

Why Every Diet Fights the Same Opponent

When you lose weight through caloric restriction your body does not cooperate passively, it adapts. Resting energy expenditure decreases, you burn fewer calories at rest than you did before losing the weight. Appetite hormones shift to increase hunger and reduce the sensation of fullness.

According to Fischer, Oberänder, and Weimann (2020), weight loss in behavioral interventions typically peaks at around six months, after which plateau and progressive regain follow. Participants typically regain 30–35% of lost weight in the first year after an intervention ends, and most return to baseline weight within three to five years regardless of which diet they followed. Sukkar and Muscaritoli (2021) documented the same hormonal and metabolic adaptations across dietary approaches, confirming that the mechanism is not specific to any one diet.

The Diet Tier, A Spectrum from Overstated to Incoherent

Atkins and Ketogenic Diets

Atkins is the predecessor of modern low-carbohydrate. The diet works in the short term through a legitimate mechanism. Severe carbohydrate restriction forces the body into ketosis, shifting its primary fuel source from glucose to fat. After an initial phase of ketosis, Atkins allows for gradual reintroduction of enough carbohydrates to end ketosis becoming a low-carbohydrate diet. True ketogenic diets aim at maintaining ketosis indefinitely by severe carbohydrate restrictions, and limiting protein as well which Atkins does not.

The problems are sustainability and the long-term evidence gap. Keating et al. (2024) document the common side effects: gastrointestinal disturbance, fatigue, dizziness, and mood changes. Longer-term concerns include dyslipidemia and kidney stone risk. Sukkar and Muscaritoli (2021) note that long-term safety remains inadequately studied. A systematic review and meta-analysis by Naude et al. (2014) found that low-carbohydrate diets show no meaningful advantage over isoenergetic balanced diets for long-term weight loss or cardiovascular risk reduction.

Paleolithic Diet

The ancestral eating premise rests on shaky anthropological ground. Hunter-gatherer diets varied enormously by geography and season; there is no single paleolithic template. Tahreem et al. (2022) found no evidence that paleolithic dietary patterns produce superior weight loss outcomes compared to other caloric restriction approaches, and long-term adherence data is poor. The weight loss appears to be a function of caloric restriction rather than anything specific to the dietary composition.

Detox Cleanses

The liver and kidneys are the body’s detoxification systems. They do not require supplemental assistance from a juice cleanse or herbal product. No detox product on the market has identified which specific toxins it removes, through which biological mechanism, or in what quantity. Available scientific reviews, including Badley and Lein (2024), consistently find that the claimed health benefits are not supported by evidence, and any transient effects do not constitute detoxification.

Intermittent Fasting, A Different Category

Intermittent fasting, and specifically time-restricted eating protocols like 16:8, is not a fad diet. It belongs in a different category because its mechanistic rationale is legitimate and its evidence base is stronger than diets discussed above.

Sousa and Almeida (2024) document modest improvements in metabolic markers associated with time-restricted eating protocols. Sukkar and Muscaritoli (2021) confirm the mechanistic plausibility while noting that long-term data remains limited and weight recovery after fasting periods ends is frequently observed.

What intermittent fasting cannot do is deliver the dramatic metabolic transformation that social media claims it can. Weight loss outcomes are modest. The long-term evidence is still developing.

The Product Tier, Where the Stakes Rise

Under the Dietary Supplement Health and Education Act of 1994 (DSHEA), supplement manufacturers are not required to demonstrate safety or efficacy before bringing products to market. The FDA does not review or approve these products before they reach store shelves. There are no credible studies on efficacy, safety, or potential interactions with medications for many of these products before they reach the market.

The research record on OTC weight loss supplements confirms this. Manore and Patton-López (2022) reviewed the clinical evidence and found consistent results: little efficacy and potentially serious risk of harm. Of commonly studied ingredients, only caffeine and green tea have any data supporting a modest effect on fat metabolism.

The Documented Harm Record

Hydroxycut: The FDA issued a public warning and recall in 2009 following reports of serious liver injuries, including at least one death. Multiple product reformulations have followed. Fong et al. (2010) documented the case series in peer-reviewed literature.

OxyElite Pro: In 2013, this product was associated with an outbreak of acute liver injury in Hawaii: 97 reported cases, multiple hospitalizations, at least one death, and at least one liver transplant. The FDA issued a warning, the manufacturer voluntarily recalled the product. Federal criminal prosecution of the manufacturer followed.

Criminal Adulteration

Some weight loss supplements do not merely fail to work. They contain undisclosed pharmaceutical drugs, substances withdrawn from the US market because they caused documented harm.

Zhivikj et al. (2024) and Manore and Patton-López (2022) document the adulteration of weight loss supplements with sibutramine, a cardiovascular drug withdrawn from the US market in 2010 due to increased risk of heart attack and stroke, and with fenfluramine, withdrawn in 1997 after causing cardiac valve damage and pulmonary hypertension. A consumer purchasing what the label describes as a herbal supplement may be ingesting a potentially dangerous pharmaceutical agent without knowing it.

The GLP-1 Supplement Frontier

Following the cultural visibility of prescription GLP-1 medications a category of supplements has emerged claiming to replicate or boost GLP-1 activity through ingredients including berberine, green tea extract, and taurine. These claims are not supported by evidence.

The FDA issued warning letters in December 2024 to products making drug-like GLP-1 claims, including Veronvy (FDA, 2024). The FTC took enforcement action against NextMed and issued a Final Order in December 2025 for deceptive GLP-1 program advertising, including fabricated testimonials and undisclosed costs.

These supplements bear no meaningful relationship to the medications whose names and mechanisms they invoke.

How to Recognize Fraud

The Federal Trade Commission publishes a plain-language guide called Gut Check: A Reference Guide for Media on Spotting False Weight-Loss Claims, a practical tool that identifies claims government-engaged scientists have determined are simply not possible. Any product making these claims is, by FTC definition, making a claim known to be false:

1. Causes weight loss of two pounds or more per week without dieting or exercise.

2. Causes substantial weight loss no matter what you eat.

3. Causes permanent weight loss even after you stop using the product.

4. Blocks the absorption of fat or calories to cause substantial weight loss.

5. Safely enables users to lose more than three pounds per week for more than four weeks.

6. Causes substantial weight loss for all users.

7. Causes substantial weight loss by wearing it on the body or rubbing it into the skin.

The next time you see a weight loss advertisement, run it against these criteria. Ethan et al. (2016) found that 40% of weight loss advertisements in mainstream media were false or misleading.

What the Evidence Actually Supports

A large-scale social media analysis by Yom-Tov and Hochberg (2022) found that the average person seeking to lose weight aims to lose 24–37 kg, while clinical trial results show actual loss of 4–7 kg, with long-term maintained loss averaging 3.1 kg.

What the evidence does support for sustainable weight management: modest, consistent changes to dietary patterns sustained over time; regular physical activity; adequate sleep; and management of the psychological dimensions of eating behavior. While they will never generate $20 billion in revenue, they produce meaningful durable health benefit without the risks documented above.

Found this article useful? Share your thoughts. Join the conversation below.

Educational content on The Metabolic Archives is free, because medical information should be accessible to everyone. If you find value and want to support the work, a paid subscription is available and genuinely appreciated. Visit the About Page for additional information.

Subscribe now

© 2026 The Metabolic Archives. All rights reserved.

In December 1950, the Nobel Committee in Stockholm awarded its Prize to Philip Hench and Edward Kendall, the men who gave Mrs. G. her life back two years earlier. The press erupted, the word miracle was used without qualification, without caveat, without the measured language that medicine is supposed to require.

Then, years later, the darker picture began to emerge. Patients on chronic cortisone therapy were developing consequences the initial trials had not predicted.

In his Nobel lecture delivered in Stockholm that same December, Philip Hench stated explicitly that cortisone appeared to act not by resolving the causes of disease but by suppressing its manifestations. However the cultural momentum of the miracle had already moved beyond any individual’s ability to slow it down. We may be living through a version of this moment right now.

A Position Statement, Before the Concerns

GLP-1 receptor agonists are genuine therapeutic breakthroughs. The cardiovascular, hepatic, and renal outcome data reviewed in Part 1 of this series are among the most compelling trial results metabolic medicine has produced. For patients with significant obesity and metabolic comorbidities, for patients with type 2 diabetes, for patients with established cardiovascular disease meeting the criteria established in the SELECT trial, these drugs when used appropriately are as close to a miracle as medicine can deliver. I am unequivocally in favor of their use in patients with legitimate clinical indications.

What We Know We Don’t Know, The Long-Term Safety Gap

GLP-1 receptor agonists have been in widespread clinical use for obesity management for approximately four years. The longest cardiovascular outcomes trials run to roughly five years of follow-up, conducted in carefully selected patient populations. The broad population now receiving these drugs, including younger adults without significant metabolic comorbidity, patients using them primarily for cosmetic weight loss, or patients with health conditions and medication combinations the clinical trials did not study, has no decade-plus safety data to draw on.

Rodent carcinogenicity studies showed statistically significant increases in thyroid C-cell adenomas at all dose levels, generating an FDA black box warning on every semaglutide product label today. Current human data are more reassuring: a large multisite international cohort study across six countries involving 98,147 GLP-1 receptor agonist users, published by Baxter and colleagues in Thyroid in 2025, found no increased risk of thyroid cancer compared to users of alternative diabetes medications over follow-up of 1.8 to 3.0 years. A 2025 propensity-matched analysis by Pollack and Stokar in Diabetes/Metabolism Research and Reviews, covering 89,646 patients with approximately one decade of follow-up, similarly found no increased thyroid cancer risk.

The authors of both studies explicitly stated that their follow-up periods are insufficient to evaluate long-term risk, and that the study populations with type 2 diabetes may not represent the growing non-diabetic cohort now using these drugs. The American Thyroid Association’s January 2025 commentary characterized the reassuring findings appropriately: promising, incomplete, and requiring longer observation. Medullary thyroid carcinoma is rare and carries long latency periods that may require decades of follow-up to fully characterize.

The Muscle Problem Few Consider

What the trials show. Clinical trial data consistently demonstrate that between 25% and 45% of weight lost on GLP-1 therapy comes from lean mass rather than fat alone. In the STEP-1 trial of semaglutide, lean mass loss accounted for approximately 40–45% of total weight lost. In SURMOUNT-1 with tirzepatide, approximately 26%. A 2025 meta-analysis of 22 randomized controlled trials by Karakasis and colleagues in Metabolism confirmed lean mass loss comprising roughly 25% of total weight loss across the drug class, with Neeland and colleagues in Diabetes, Obesity and Metabolism in 2024 reviewing the mitigation strategies in detail. The proportion of lean mass loss is modifiable with structured resistance exercise three to five days per week and adequate dietary protein intake, Case series published in PMC in 2025 demonstrate that patients can maintain or even gain lean mass while losing significant fat under supervised conditions.

Why muscle mass is not merely cosmetic. Skeletal muscle accounts for approximately 70–80% of whole-body insulin-stimulated glucose disposal. Less widely appreciated is what Richter and Hargreaves documented in their foundational 2013 review in Physiological Reviews: muscle contraction stimulates glucose uptake through a pathway that is independent of insulin, via GLUT4 transporter translocation driven by the contraction itself, mediated through AMPK activation rather than insulin receptor signaling.

In plain language: when you exercise, your muscles pull glucose out of the bloodstream through a door that does not require insulin to open. For a patient with insulin resistance, exercising muscle is one of the few remaining mechanisms through which glucose can be cleared efficiently. When you reduce the mass of the tissue capable of performing that function, you reduce the metabolic benefit of exercise itself. While exercise remains beneficial, its capacity to compensate for insulin resistance has been diminished.

The functional dimension. Muscle mass is also the biological substrate of physical independence: the capacity to climb stairs, rise from a chair without assistance, carry groceries, maintain balance, recover from illness. Sarcopenia (muscle mass loss) in older adults is one of the leading drivers of functional independence loss and increased mortality risk.

The age dimension. The biology of muscle recovery becomes more difficult with age. This is a well-characterized physiological phenomenon called anabolic resistance, defined as the age-related blunting of the muscle protein synthetic response to both protein intake and resistance exercise. Breen and Phillips, publishing in PubMed in 2013, established the mechanistic basis; Aragon, Tipton, and Schoenfeld in Nutrition Reviews in 2023 reviewed the question of whether this resistance is inevitable or preventable; and a 2023 review in Nutrients/PMC examined the specific interventions capable of counteracting it. Aging muscle is less sensitive to lower doses of amino acids and responds less robustly to resistance exercise than younger muscle.

You Don’t Return to Where You Started

The STEP-4 trial established clearly that stopping semaglutide leads to substantial weight regain in most patients within months (Wilding et al., NEJM, 2022). Budini and colleagues’ 2025 systematic review and meta-regression on medRxiv confirmed the trajectory. What is less discussed is the likely composition of that regained weight.

Weight lost on GLP-1 therapy includes a meaningful proportion of lean mass. Weight regained after discontinuation follows the well-established pattern of caloric restriction recovery: muscle is preferentially catabolized during restriction, and fat is preferentially restored during repletion. This physiological asymmetry, compounded by anabolic resistance in older patients, means a patient who stops the drug and regains their weight has not simply returned to their starting point, they may have more fat, less muscle, and a reduced capacity to recover the lean tissue that was lost. Shah and colleagues’ 2026 analysis in Diabetes, Obesity and Metabolism addresses the clinical management implications of this trajectory. The body composition data on the regain phase specifically remains limited, this is a physiologically sound inference from established biology, not a directly measured outcome in GLP-1 discontinuation studies.

The patient who discontinues the drug without the muscle-preservation infrastructure in place may be in a worse metabolic position than before they started.

An Emerging Adverse Effect Worth Noting

Post-marketing surveillance has generated reports of delayed gastric emptying severe enough to be classified as gastroparesis (partial or complete loss of gastrointestinal motility) in some patients on GLP-1 therapy. The FDA label for semaglutide states explicitly that it is not recommended in patients with severe gastroparesis. Whether this represents a true drug-induced complication or reflects the detection of pre-existing gastrointestinal dysmotility in a population already at elevated risk remains an actively investigated question; direct causality has not been established.

The Commercial Prescribing Problem

The concern here is with a specific commercial model: an online platform that profits from selling a drug, conducts a brief assessment without physical examination, laboratory evaluation, or assessment of relevant comorbidities, prescribes the drug without establishing baseline body composition or nutritional status, provides little or no structured dietary or resistance exercise counseling, and offers minimal ongoing clinical monitoring.

The evidence for concern is documented and specific. A survey of 2,000 primary care physicians conducted by Omada Health and reported in the Medical Liability Monitor in March 2025 found that 67% believe GLP-1 prescriptions by third-party telehealth providers pose a significant patient safety risk. 77% of those same physicians reported conducting a thorough physical evaluation before prescribing, assessing for comorbidities including diabetes, cardiovascular disease, and hypertension. More than half require patients non-pharmacological interventions before considering a prescription. Published literature reviewed in a 2025 PMC analysis of access to GLP-1 medications, documents that many online platforms ship compounded GLP-1 drugs after a questionnaire only, with no laboratory work, lifestyle counseling, or in-person physician visit required. As reported by STAT News in March 2026, the FDA has issued warning letters to more than 70 telehealth companies regarding their marketing of compounded GLP-1 medications. State medical boards have taken disciplinary action against prescribers operating through platforms that failed to meet minimum standards for establishing a legitimate physician-patient relationship. Golovaty and Hagan, writing in the New England Journal of Medicine in February 2024, identified the structural tensions between direct-to-consumer prescribing models and responsible clinical practice.

The patients most at risk by this model are those the drug is least likely to serve appropriately: patients without significant metabolic disease seeking a cosmetic result, who will not receive the dietary and exercise guidance that protects lean mass, and who will discontinue when the cost becomes unsustainable or the side effects intolerable.

What Responsible Use Actually Looks Like

These drugs, used correctly, are remarkable. Used correctly means: clear clinical indications, comprehensive baseline assessment including laboratory evaluation and body composition, structured dietary counseling with specific attention to protein intake adequate to protect lean mass during weight loss, resistance exercise as a component of the treatment plan, regular monitoring of weight, body composition, and metabolic parameters throughout treatment. It also means an honest conversation with every patient about the lifelong nature of this commitment before prescribing, not after six months when side effects or financial limitations threaten compliance.

And so I leave you dear reader, with this caution:

“Those who cannot remember the past are condemned to repeat it.” — George Santayana, The Life of Reason, 1905

Found this article useful? Share your thoughts. Join the conversation below.

Educational content on The Metabolic Archives is free, because medical information should be accessible to everyone. If you find value in it and want to support the work, a paid subscription is available and genuinely appreciated. Visit the About Page for additional information.

Subscribe now

© 2026 The Metabolic Archives. All rights reserved.

September 21, 1948 a 29-year-old woman known to history only as Mrs. G, lay bedridden in Saint Marys Hospital in Rochester, Minnesota. Severe rheumatoid arthritis had stripped her of the ability to care for herself independently. That morning, under the direction of physicians Philip Hench and Edward Kendall, she received her first injection of Compound E, a synthetic steroid that would later be called cortisone. Three days later, she was markedly improved. Within a week, she had taken a three-hour shopping trip. Her words to her doctors: “I have never felt better in my life.”

Medicine has witnessed a handful of moments like this when a discovery lands with such force that the profession and the public both struggle to absorb what they are seeing.

Where It Began, The Gut Talks to the Pancreas

The story of GLP-1 begins with a deceptively simple observation. When you eat a meal and glucose enters your bloodstream, your pancreas releases insulin to manage it. Researchers had understood that mechanism for decades. What they had not fully appreciated was that the gut itself actively participates in that signal.

The phenomenon is called the incretin effect: oral glucose produces a substantially greater insulin response than the same amount of glucose delivered directly into the bloodstream. As Baggio and Drucker described in their foundational 2007 review in Gastroenterology, glucagon-like peptide-1 (GLP-1) is the primary messenger responsible for this effect. It is produced by the L-cells of the distal small intestine and colon in response to food intake, and travels through the bloodstream to receptors throughout the body including the pancreas, brain, heart, liver, and kidneys.

The problem is the body degrades its own GLP-1 within approximately two minutes. A hormone that disappears before it can be clinically useful is of limited therapeutic value. The solution arrived from an unlikely source.

The Gila Monster Detour

The Gila monster, a large, venomous lizard native to the American Southwest, produces a compound in its saliva called exendin-4. Structurally, it is remarkably similar to human GLP-1. Functionally, there is a critical difference: the enzyme that destroys GLP-1 in minutes cannot break down exendin-4. Exenatide (Byetta), synthesized from exendin-4, became the first GLP-1 receptor agonist approved by the FDA in 2005, as Sharma and colleagues documented in International Immunopharmacology in 2018. The lineage from lizard saliva to semaglutide, the active molecule in Ozempic and Wegovy, runs in a straight line through two decades of pharmaceutical refinement aimed at a single goal: a compound that mimics GLP-1 durably enough to be therapeutically useful.

How GLP-1 Works, The Pancreas

GLP-1 receptor agonists stimulate insulin secretion from the pancreas only when blood glucose is already elevated. When glucose is normal, the signal quiets. This glucose-dependent mechanism is the reason these drugs do not cause hypoglycemia (low blood glucose) the way older diabetes medications do.

The drugs also suppress glucagon, the hormone released from alpha cells that ordinarily raises blood sugar between meals. In people with type 2 diabetes, glucagon is chronically elevated, contributing to persistently high fasting glucose. GLP-1 receptor activation pulls that glucose release back toward normal.

Finally, they slow gastric emptying, the rate at which food leaves the stomach and enters the small intestine. Nutrients absorbed more gradually produce a shallower, more manageable rise in blood glucose after meals.

How GLP-1 Works, The Brain and Food Noise

GLP-1 receptors exist throughout the brain: in the hypothalamus and brainstem, which regulate hunger and satiety, and in the brain’s reward circuitry, including the nucleus accumbens and the ventral tegmental area.

GLP-1 receptor activation in the hypothalamus and brainstem produces satiety signals and does so before a meal is finished, not after. A 2024 study published in Science by Kim and colleagues identified specific neurons in the dorsomedial hypothalamus that encode what researchers call preingestive satiation. GLP-1 receptor agonists amplify these neurons specifically during eating.

GLP-1 receptors in the reward centers modulate dopamine signaling reducing the motivational and emotional pull of food. This is the neuroscience behind what patients describe as food noise going quiet.

Food noise is the intrusive, repetitive mental preoccupation with food that many people with obesity experience as a cognitive and emotional compulsion. A 2025 review in PMC describes this as dysregulation of the brain’s default mode network and reward circuits. For many patients on GLP-1 medications, this signal diminishes or disappears entirely. This food noise is one reason why obesity is so difficult to manage through behavioral intervention alone.

The mechanism for GLP-1’s brain effects is strong in animal models and supported by emerging human neuroimaging data. Circuit-level specificity in humans continues to be established. A 2025 PMC review on GLP-1 modulation of craving and addiction characterizes the state of the evidence accurately: the broad framework is well-supported; some of the more granular claims remain areas of active investigation.

How GLP-1 Works, The Heart and Blood Vessels

GLP-1 receptors are expressed in heart muscle cells and the cells lining blood vessel walls. The drugs suppress inflammatory markers including TNF-α and IL-6, inhibit the formation of arterial plaques, stimulate nitric oxide production in endothelial cells, and reduce oxidative stress.

The clinical confirmation of this is the SELECT trial. Lincoff and colleagues, publishing in the New England Journal of Medicine in 2023, demonstrated that semaglutide 2.4mg weekly produced a 20% reduction in major adverse cardiovascular events over a mean follow-up of 34 months, in patients with obesity and established cardiovascular disease but without type 2 diabetes. Crucially, a pre-specified analysis of SELECT published in The Lancet in 2025 established that only approximately 33% of this cardiovascular benefit was attributable to reductions in waist circumference, at least two-thirds of the protection comes from mechanisms beyond weight loss itself.

Both the American College of Cardiology and the European Society of Cardiology now carry Class I, Level A recommendations for GLP-1 receptor agonists in patients with type 2 diabetes and established cardiovascular disease. These drugs appear to protect the heart and blood vessels through their own direct biological action not merely through weight reductions.

How GLP-1 Works, The Liver

Metabolic dysfunction-associated steatotic liver disease (MASLD), formerly called non-alcoholic fatty liver disease or NAFLD or just fatty liver is the most prevalent chronic liver disease worldwide, affecting an estimated 38% of the global population. It is driven by the same constellation of insulin resistance, excess visceral fat, and systemic metabolic dysfunction that GLP-1 medications address.

In August 2025, the FDA granted accelerated approval to semaglutide 2.4mg weekly for the treatment of MASH (metabolic dysfunction-associated steatohepatitis) the more severe inflammatory stage of the disease with moderate to advanced fibrosis. The approval was based on the phase 3 ESSENCE trial. As reported in updated AASLD Practice Guidance published in Hepatology in 2025, at 72 weeks, 62.9% of patients achieved resolution of steatohepatitis without worsening of fibrosis, compared to 34.3% on placebo. Fibrosis improvement was achieved in 36.8% versus 22.4% on placebo. Both primary endpoints reached high statistical significance.

There is an important nuance worth understanding, the liver does not express significant GLP-1 receptors. The hepatic benefits are mediated indirectly through the drug’s systemic effects on insulin sensitivity, weight, inflammation, and lipid metabolism, operating through the brain, gut, adipose tissue, and pancreas.

How GLP-1 Works, The Kidneys

The organ-protective effects of GLP-1 therapy extend further still. The FLOW trial demonstrated a 24% reduction in major kidney disease events with semaglutide 1mg weekly in patients with type 2 diabetes and chronic kidney disease, as documented in a 2025 PMC review on cardiovascular-kidney-metabolic syndrome management. The renal benefits appear to be mediated through improvements in blood pressure, inflammation, and metabolic dysfunction rather than through direct kidney GLP-1 receptor action, though research in this area continues.

GLP-1 therapy is no longer accurately described as a diabetes drug with a weight loss benefit. It is increasingly understood as a systemic metabolic intervention with organ-protective effects across multiple systems simultaneously.

The Next Generation: Tirzepatide and Dual Agonism

Tirzepatide, sold as Mounjaro for type 2 diabetes and Zepbound for obesity, adds a second mechanism to GLP-1 receptor activation. It also activates receptors for GIP, glucose-dependent insulinotropic polypeptide, another incretin hormone with overlapping but non-identical distribution in the brain and peripheral tissues. The synergy between these two receptor pathways appears to produce greater weight loss than GLP-1 activation alone.

The SURMOUNT-5 trial, published in the New England Journal of Medicine in May 2025, was the first direct head-to-head comparison of tirzepatide against semaglutide in patients with obesity without type 2 diabetes. Aronne and colleagues reported that tirzepatide produced 20.2% mean body weight loss versus 13.7% for semaglutide at 72 weeks, a 47% greater relative reduction. Nearly twice as many tirzepatide participants achieved 25% or greater weight loss. The gastrointestinal side effect profiles were broadly comparable, though tirzepatide showed slightly higher rates of treatment discontinuation due to GI effects (5.6% versus 2.7%). Is worth pointing out this trial was open-label and funded by Eli Lilly, maker of Tirzepatide.

The precise mechanism by which adding GIP agonism amplifies weight loss remains under active investigation. If this trial results are to be taken at face value (paint me a skeptic here), it suggests dual receptor activation produces outcomes approaching those previously seen only with bariatric surgery.

Side Effects and the Discontinuation Reality

The most common adverse effects are gastrointestinal: nausea, vomiting, diarrhea, constipation. These are dose-dependent, most prominent during the dose escalation phase, and resolve or diminish for most patients over time. Rare but serious side effects include acute pancreatitis, symptomatic gallbladder disease, acute kidney injury from dehydration in the context of severe GI symptoms, and progression of diabetic retinopathy in patients with pre-existing retinopathy. A 2024 review by Tobaiqy in Endocrinology and Metabolism Clinics of North America provides a systematic account of the serious adverse event profile from trial and real-world data.

Studies in rodent receiving high doses of GLP-1 exhibited thyroid C-cell hyperplasia and increased rates of medullary thyroid carcinoma (MTC). That potential concern led to an FDA black box warning on semaglutide products. Is important to note that thyroid C-cells in rodents express GLP-1 receptors at higher density than in humans. While no evidence of increased incidence of MTC associated to GLP-1 drugs has been noted in humans so far, the scientific community remains vigilant.

The STEP-4 trial established that stopping semaglutide leads to reversal of most metabolic benefits, including substantial weight regain, within months (Wilding et al., NEJM, 2022). A 2025 systematic review and nonlinear meta-regression by Budini and colleagues on medRxiv confirmed the trajectory of regain following cessation of GLP-1 receptor agonists. A 2026 analysis by Shah and colleagues in Diabetes, Obesity and Metabolism addressed the clinical management implications.

The underlying metabolic dysfunction that the drug manages does not disappear when the drug stops. For most patients with significant metabolic disease, GLP-1 therapy is a lifelong commitment, not a defined course of treatment with an end point.

These are powerful tools and need to be used with the same care and precision that the science behind them reflects. Part 2 examines what that means in practice and what happens when it doesn’t.

Found this article useful? Share your thoughts. Join the conversation below.

Educational content on The Metabolic Archives is free, because medical information should be accessible to everyone. If you find value and want to support the work, a paid subscription is available and genuinely appreciated. Visit the About Page for additional information.

Subscribe now

© 2026 The Metabolic Archives. All rights reserved.

Part 1 of this series laid out what obesity is and what drives it: from ultra-processed food environments to chronic stress, sleep deprivation, psychiatric factors, family conditioning, cultural food traditions, and the structural realities of the built environment.

This post takes you inside your body to show you what obesity is actually doing once it is established and more importantly, what you can do about it at every stage.

Your Body Has a Thermostat

Your body has a sophisticated biological system designed to keep energy balance stable without requiring conscious effort from you. Think of it as the thermostat that monitors incoming and outgoing energy and makes continuous adjustments to maintain equilibrium. This system works through a coordinated cast of hormones each playing a specific role:

Ghrelin is produced primarily in the stomach and signals hunger to the brain. It rises before meals and falls after eating.

Leptin is produced by fat cells and signals fullness and energy sufficiency. When fat stores are adequate, leptin tells the brain to reduce appetite and increase energy expenditure.

GLP-1 and PYY are released from the gut after meals and reinforce satiety, slowing gastric emptying and reducing the drive to keep eating.

Insulin, produced by the pancreas, manages blood glucose by facilitating uptake into cells. It exerts additional metabolic effects through other mechanisms.

Cortisol, the primary stress hormone, mediates the body’s response to threat and affects appetite, fat distribution, and metabolism.

Dopamine drives the brain’s reward and craving circuitry, making certain foods feel compelling and rewarding (i.e., sweets binging after a breakup).

When this system functions properly, energy balance is largely self-regulating. You eat, satiety signals rise, appetite decreases, you stop. You burn energy, fuel stores deplete, hunger signals rise, you eat again. The thermostat maintains its set point automatically without additional intervention needed.

How the Thermostat Breaks

As visceral fat accumulates it releases excess free fatty acids and pro-inflammatory molecules that travel to the liver, muscle, and pancreas, triggering low-grade systemic inflammation that progressively impairs insulin signaling throughout the body. This mechanism is well-documented in a 2021 adipose tissue review published in ScienceDirect. The fat itself becomes an active participant in disrupting the systems that regulates it.

Leptin resistance develops when the brain loses its ability to respond to the fullness signals accurately. In obesity, leptin levels in the bloodstream are actually elevated, fat cells are producing higher amounts. But obesity impairs leptin’s transport across the blood-brain barrier by reducing the specific molecular transporters that carry it through, according to a 2025 PMC review of leptin resistance mechanisms. The result, as documented in a 2021 paper in Frontiers in Endocrinology, is reduced satiety, continued overconsumption, and progressive weight gain.

Insulin resistance develops as systemic inflammation and visceral fat accumulation impair insulin signaling, and cells throughout the body become less responsive to it. The pancreas compensates by producing more and more insulin. Blood sugar control becomes increasingly impaired. Critically, research published in MDPI Biomedicines in 2025 suggests that adipose tissue insulin resistance often precedes systemic insulin resistance and the clinical diagnosis of diabetes by several years meaning the metabolic cascade is well underway long before standard blood tests would catch it. A 2024 PMC analysis found that visceral fat carries stronger predictive value for adipose tissue insulin resistance than BMI, waist circumference alone, or total body fat percentage; more on that below.

Excess visceral fat degrades the regulatory system. The degraded regulatory system makes it harder to reduce visceral fat. Inflammation and insulin resistance generate their own momentum with the process becoming increasingly self-sustaining.

The Four Stages and Where You Want to Be

Stage 1: Subcutaneous obesity. Excess fat is accumulating primarily beneath the skin. Metabolic disruption is minimal. The thermostat is functioning, even if energy balance is off. This is the stage where lifestyle intervention has maximum power, before subcutaneous stores become overburden leading to visceral fat accumulation.

Stage 2: Visceral fat accumulation. Fat is deepening into the abdominal cavity, surrounding the organs triggering inflammation. Leptin transport is starting to become impaired. Intervention at this stage is still highly effective but the biology is beginning to work against you rather than with you.

Stage 3: Established insulin resistance. The pancreas is compensating. Blood glucose regulation is impaired. The system is no longer simply dysregulated, it is defending the dysregulation. Intervention here is still meaningful and important, but it requires more sustained effort and often benefits from medical support.

Stage 4: Full metabolic syndrome. A convergence of abdominal obesity, elevated blood glucose, high blood pressure, abnormal lipid levels, and systemic inflammation operating simultaneously. This is where the most serious downstream diseases, type 2 diabetes, cardiovascular disease, fatty liver disease, and others, become immediate rather than distant risks.

Your agency to interrupt this process is greatest at Stage 1 and diminishes progressively across the spectrum.

The concept of “metabolically healthy obesity”, the idea that some people carry significant excess weight without metabolic consequences, is real in the short term and genuinely misleading in the long term. Longitudinal data from the MESA study, published in JACC in 2018, found that a substantial proportion of individuals in the metabolically healthy obesity category transition to metabolic disease over time, at a rate that tracks with cumulative obesity duration and severity.

A Simple Tool You Can Use Right Now

Weight and BMI alone are poor proxies for metabolic risk. The essential point here is simpler: where fat is located matters more than how much you weigh.

The tool that captures this most practically is the waist-to-height ratio. Is a simple screening tool has a good track record for identifying people at increased metabolic risk.

Here is what you can do at home. Find a piece of string. Cut it to your height. Fold it in half. Now try to wrap that folded string around your waist at the level of your navel. If it does not reach, if your waist circumference is greater than half your height, that is a reason to seek additional metabolic evaluation from your doctor as soon as possible.

This assessment costs nothing, requires no equipment beyond a piece of string, and takes about thirty seconds. Research published in PMC in 2024 confirms that visceral fat is the strongest predictor of adipose tissue insulin resistance when compared to BMI, waist circumference alone, and total body fat.

A Word on Dignity and the Cultural Conversation

There is an active public debate about body acceptance, weight stigma, and whether obesity is a health issue or primarily a social one.

Three things are simultaneously true, and none of them cancels the others:

1. Better public accommodation for people living with obesity is reasonable, practical, and worthy goal. It is just basic dignity.

2. Weight stigma causes documented and serious harm. According to a 2020 joint international consensus statement in Nature Medicine, stigma is associated with healthcare avoidance, reduced utilization of medical services, worsened eating behavior, lower physical activity, and increased weight gain over time. AAFP data from 2022 indicates that nearly 70% of people with overweight or obesity report feeling stigmatized by physicians and women in particular delay seeking care to avoid weight-related shame. A 2024 review documented fewer cancer screenings and less intensive diabetes management in patients with obesity, showing that stigma causes not just emotional harm, but a concrete clinical one.

3. The evidence that obesity is health-neutral is not there. The American Heart Association’s 2021 scientific statement in Circulation is unambiguous: obesity leads to cardiovascular disease and cardiovascular mortality independent of other cardiovascular risk factors. The full list of well-documented independent health consequences, type 2 diabetes, hypertension, fatty liver disease, obstructive sleep apnea, osteoarthritis, several cancers, shortened life expectancy, is extensive, as compiled in a 2025 review in Diabetes, Obesity and Metabolism. Acknowledging these consequences is not a form of stigma. Pretending they do not exist in the name of compassion is not a kindness.

What You Can Do Starting Now

1. Assess your actual metabolic risk today. Measure to waist-to-height ration. If your waist circumference exceeds half your height, make an appointment with your physician and ask specifically for a metabolic evaluation.

2. Begin reducing ultra-processed foods. The goal at the beginning is not perfection, is reduction. For every ultra-processed item in your regular diet, identify one whole-food alternative that you can realistically prepare and enjoy. Start with the meal where ultra-processed food is most dominant and make one replacement there. The evidence base on UPFs is consistent enough that even partial reduction produces measurable benefit.

3. Prioritize sleep as a metabolic intervention. Research consistently links short sleep duration to increased caloric intake, preferential craving for high-reward foods, and impaired metabolic regulation. Assess what is limiting your sleep and address it: screen time before bed, irregular sleep schedules, sleep apnea that has never been evaluated, and chronic stress are the most common culprits. Aim for seven to nine hours of sleep daily.

4. Introduce structured movement. The evidence on physical activity and metabolic health is unambiguous: even modest, consistent movement significantly improves insulin sensitivity, reduces visceral fat, lowers blood pressure, and improves lipid profiles. The American Heart Association recommends at least 150 minutes per week of moderate-intensity aerobic activity, roughly 22 minutes per day, as a minimum threshold for cardiovascular and metabolic benefit. If that feels out of reach at the start, shorter sessions of 10–15 minutes are still metabolically meaningful and a legitimate starting point. The goal is consistency before intensity, walking is sufficient. Walking after meals, in particular, has well documented benefit for post-meal blood sugar control.

Remember to consult your physician before starting any exercise program to determine if it is safe for you.

5. Address stress deliberately. Chronic cortisol elevation drives visceral fat, insulin resistance, and systemic inflammation. Evidence-based stress reduction approaches including mindfulness-based stress reduction (MBSR), regular physical activity, adequate sleep, and social connection, have documented physiological effects on cortisol levels and metabolic markers. If your stress load is driven by circumstances that require structural change (financial, relational, occupational), is important to implement strategies to address them as soon as possible.

6. If psychiatric factors are in the picture, address them directly. If depression, anxiety, or a history of trauma is contributing to the pattern described above, treating those conditions is essential in the treatment of your metabolic health. Food is used as an emotional regulator by many people, often without full awareness, and often as a learned response to environments where other forms of comfort were unavailable. Working with a qualified mental health professional is a necessary intervention.

7. Engage your physician as an active partner. Time constraints in modern medical practice mean that the conversation about metabolic health often does not happen in the depth it deserves. You can change that by showing up with specific questions: Where am I on the metabolic risk spectrum? What are my fasting glucose and HbA1c? Do I have insulin resistance? What screening tests do I need? The physician-patient relationship works best when you are an informed, active participant rather than a passive recipient.

Found this article useful? Share your thoughts. Join the conversation below.

Educational content on The Metabolic Archives is free, because medical information should be accessible to everyone. If you find value and want to support the work, a paid subscription is available and genuinely appreciated. Visit the About Page for additional information.

Subscribe now

© 2026 The Metabolic Archives. All rights reserved.

Obesity is the most visible symptom of an underlying and progressive metabolic disorder that begins silently, advances predictably, and becomes increasingly difficult to reverse the longer it goes unaddressed.

What Obesity Actually Is

At its most basic, obesity is the result of sustained imbalance between energy intake and energy expenditure. While this simple definition is accurate at the beginning. the underlying mechanisms become more complex the longer the imbalance continues. Once obesity is established the body’s own regulatory systems begin to change in ways that make the imbalance harder to correct.

The fat that accumulates deep in the abdomen surrounding internal organs is metabolically active. This visceral fat is the warning marker, more meaningful than the number on your scale. For pre-menopausal women in particular, a shift toward abdominal fat is more clinically significant.

The Forces That Drive It

Ultra-Processed Foods:

Ultra-processed foods, the industrially manufactured products that now make up the majority of calories consumed in the United States, are designed to make overconsumption easy and stopping difficult. Multiple systematic reviews and meta-analyses confirm a strong association between ultra-processed food consumption and increased risk of obesity, type 2 diabetes, hypertension, and dyslipidemia, as documented in a 2024 review in Advances in Nutrition.

Emerging research published in Frontiers in Nutrition in 2026 suggests that even when ultra-processed foods are matched calorie-for-calorie and nutrient-for-nutrient against minimally processed alternatives, they still promote greater energy intake likely through structural disruption of the food matrix that reduces chewing requirements, accelerates eating rate, and impairs the body’s satiety signaling. As a 2024 analysis in Current Nutrition Reports details, multiple overlapping mechanisms are involved, including hyper palatability, poor fiber content, and disruption of hunger-regulating hormones. The specific hormonal pathways remain under active investigation; the behavioral outcome, you eat more, and feel less satisfied, is the more consistently supported finding.

If you eat a diet heavy in ultra-processed foods, the struggle to control your intake is the predictable biological response to food specifically engineered to override your satiety mechanisms.

Chronic Stress:

Stress does not merely make you reach for comfort food, though it does that too. Prolonged elevation of cortisol, the body’s primary stress hormone, is linked to visceral fat deposition, insulin resistance, and systemic inflammation through dysregulation of the HPA (hypothalamic-pituitary-adrenal) axis, according to a 2024 review in PMC. The combination of chronic stress with a diet high in fat and sugar appears to be a more potent driver of abdominal fat accumulation than diet alone, mediated in part by a signaling molecule called neuropeptide Y.

Chronic psychosocial stress, the sustained kind that comes from financial insecurity, difficult relationships, job pressure, or living in an unsafe environment, is associated with insulin resistance independently of abdominal obesity. The stress itself, not just the weight it drives, is doing metabolic damage independently.

People in lower-income environments, high-demand and low-control jobs, navigating systemic disadvantage, carry disproportionate chronic stress loads reflected directly by increased metabolic disease rates.

Sleep Deprivation:

Think about what you want to eat after a night of poor sleep; not salad or something healthy. The pull is toward something dense, sweet, high-reward instead. Experimental research in controlled settings consistently shows that sleep restriction increases caloric intake and drives preferential craving for high-carbohydrate, high-reward foods. The American Heart Association has identified disrupted appetite-regulating hormones as a key mechanism between short sleep duration and obesity risk, as reported in a 2025 GSSI Sports Science Exchange summary.

The exact hormonal mechanism, how much of this is ghrelin or leptin, or how much is neurological reward circuitry, is still being investigated. What is consistent is the behavioral outcome: you eat more, you eat worse, and you feel less in control of it.

Depression, Anxiety, and the Psychiatric Dimension:

Depression and anxiety are among the most significant and most under acknowledged drivers of obesity. Depression disrupts sleep, reduces motivation for physical activity, alters appetite regulation, and frequently drives emotional eating as a coping mechanism. Anxiety elevates cortisol chronically. Both conditions impair the capacity for deliberate that is required to sustain lifestyle changes under difficult circumstances.

People living with untreated or under treated depression are managing a serious illness with limited resources, and the obesity that follows is a downstream consequence of that illness.

A substantial body of research links adverse childhood experiences, including physical, sexual and emotional abuse, neglect, and household dysfunction, to elevated rates of obesity, metabolic syndrome, and cardiovascular disease in adulthood. The mechanisms are multiple: disrupted stress-response systems, altered appetite regulation, increased risk of depression and anxiety, and the use of food for emotional regulation as a coping mechanisms in childhood environments.

If you see yourself in any of this, the best decision is to seek treatment, in many cases it means working with a mental health professional alongside whatever metabolic interventions you pursue.

Family, Culture, and the Food You Grew Up With:

Eating habits are not formed in a vacuum. They are transmitted from parents to children, through family rituals, cultural traditions. The foods you eat habitually in childhood become the foods your palate and your body consider normal.

Many traditional food cultures developed their culinary patterns in an era where intense physical labor was the daily reality. The calorie-dense, fat/carbohydrate-rich foods of agricultural and working-class traditions were appropriate to the energy demands of the people who created them.

Those foods eaten in large quantity in a sedentary 21st-century life produce a very different metabolic outcome. The mismatch between its energy density and decreased energy demands of modern life became a real problem.

We don’t need to abandon cultural food traditions, just need to adjust them to match our modern reality. It is also worth noting that within families, children who grow up watching parents reach for food in response to stress, boredom, or emotional pain learn that pattern as a primary coping tool as well.

The Built Environment:

Food deserts, geographic areas where affordable, nutritious food is scarce or inaccessible and ultra-processed options are abundant, disproportionately affect lower-income urban and rural communities. When a convenience store is within walking distance but the nearest grocery store requires a car trip you cannot reliably make, the food choices available to you become restricted.

Sedentary built environments, suburbs designed around cars rather than walking, workplaces requiring hours of sitting, entertainment that is entirely screen-based, neighborhoods without safe outdoor spaces, systematically eliminate the incidental physical activity that previous generations enjoyed.

These structural factors do not excuse inaction, they explain why “just exercise more and eat less” lands very differently depending on where and how you live.

Non-Exogenous Causes:

Some obesity is driven not primarily by environment and behavior but by medical conditions that alter metabolism (hypothyroidism, Cushing’s syndrome, polycystic ovary syndrome), by medications that cause weight gain as a physiological effect (some antidepressants, antipsychotics, corticosteroids, insulin), or by genetic factors that shape energy regulation, fat distribution, and appetite in ways that are not under voluntary control.

If you suspect your weight is driven by a medical condition or medication, seeking proper medical attention to address those is the recommended course of action.

How Serious Is This

According to the CDC’s September 2024 National Health and Nutrition Examination Survey data brief, 40.3% of American adults had obesity during the August 2021 to August 2023 measurement period. That is two in every five people you encounter on any given day. And within that figure, severe obesity continued to rise even as overall rates showed signs of leveling.

Medical costs for adults with obesity run approximately $1,900 more per year than for adults at a healthy weight, rising to over $3,000 annually for those with severe obesity, per CDC Adult Obesity Facts, 2024. The total annual economic burden (direct healthcare costs and lost productivity) exceeds $1.4 trillion in the United States, according to analysis cited by the Obesity Medicine Association from the Milken Institute.

There is one encouraging finding worth naming: according to the Trust for America’s Health and CDC BRFSS data for 2024, for the first time in over a decade, the number of states with obesity rates above 35% declined. Researchers caution that it is too early to call this a trend rather than a fluctuation.

What Comes Next

You now have the better picture of what drives obesity. The forces at work are biological, psychological, cultural, and structural and they operate simultaneously, reinforcing each other.

Part 2 takes you inside your body to show you what obesity is actually doing, how your hormonal regulatory system degrades, why the process becomes self-perpetuating, and where your real window of agency lies. It also gives you a simple, free self-assessment tool you can use today, and a complete set of specific, actionable steps you can begin implementing immediately.

Found this article useful? Share your thoughts. Join the conversation below.

Educational content on The Metabolic Archives is free, because medical information should be accessible to everyone. If you find value and want to support the work, a paid subscription is available and genuinely appreciated. Visit the About Page for additional information.

Subscribe now

© 2026 The Metabolic Archives. All rights reserved.

In a recent post — The New Dietary Guidelines: What They Got Right, What They Got Wrong — we examined the new 2025–2030 Dietary Guidelines for Americans. After that piece was finalized, the American Heart Association published a significant update to its standing dietary guidance in Circulation. This post discuss the guideline including where it agrees with the federal dietary guidelines, where it directly contradicts them, and where my own clinical position diverges from both.

Why This Update Matters

In January 2026, the American Heart Association published an update to its standing dietary guidance scientific statement in Circulation. The lead author, Alice Lichtenstein of Tufts University, also led the 2021 version. The 2025–2030 Dietary Guidelines for Americans were finalized just months earlier, and in several areas, the two documents point in opposite directions.

The Nine Core AHA Recommendations

The 2026 statement organizes its guidance into nine evidence-based principles.

One: Adjust energy intake and expenditure to maintain a healthy body weight. Not a revolutionary statement, but its placement first is deliberate. Weight management is not an aesthetic priority in this document, is a foundational cardiovascular risk variable.

Two: Eat a wide range of vegetables and fruits, whole forms over juice. The reasoning is straightforward: juice strips fiber. Fiber is a core part of the nutritional package, shaping how quickly sugar enters the bloodstream and how the gut microbiome responds. More on fiber below.

Three: Choose whole grains over refined grains. The same logic applies. Refining grain removes the bran and germ leaving primarily starch. A 2021 meta-analysis in The BMJ found that each 90-gram daily serving of whole grains was associated with a 19% lower risk of cardiovascular disease mortality (Reynolds AN, et al. BMJ. 2021;374:n1706).

Four: Choose healthy sources of protein, prioritizing plant-based sources over meat. Fish and seafood are recommended for their omega-3 content. Red meat is specifically advised against due to its saturated fat content and its association with increased cardiovascular disease risk. This recommendation explicitly departs from the 2025–2030 federal dietary guidelines, which recommend increased red meat consumption as part of a healthy dietary pattern. More on that below.

Five: Choose unsaturated fats over saturated fats. The AHA recommends cooking oils such as olive oil and canola oil over animal fats including butter and beef tallow. The federal guidelines list butter and beef tallow as healthy fat sources.

Six: Choose minimally processed foods instead of ultra-processed foods. The AHA links dietary patterns high in ultra-processed foods to overweight, obesity, cardiovascular disease, type 2 diabetes, and all-cause mortality, citing a 2024 umbrella review in The BMJ that aggregated 45 meta-analyses covering 9.9 million participants (Ultra-processed food exposure and adverse health outcomes, BMJ. 2024;384:e077743). Critically, the AHA statement acknowledges a modern reality: food insecurity and cost are genuine barriers to following whole-food guidance. Marketplace-level change is required to make these recommendations accessible across income levels.

Seven: Minimize added sugars in beverages and foods. Added sugar drives caloric surplus, promotes insulin resistance, and fails to generate satiety signals proportional to its caloric load. The evidence base here is among the most consistent in nutrition science.

Eight: Choose low-sodium foods and prepare food with minimal or no salt. More than 70% of the sodium Americans consume, comes from packaged foods and restaurant meals not the salt shaker, according to CDC dietary surveillance data. The 2026 AHA statement adds something new in this cycle, an explicit emphasis on potassium as a companion recommendation. Sodium and potassium operate as a physiological teeter-totter: excess sodium raises blood volume and blood pressure, while potassium promotes sodium excretion through urine and relaxes blood vessel walls. Increasing potassium intake from whole food sources (legumes, leafy greens, avocados, fish) is now an explicit AHA dietary target alongside sodium reduction. For anyone managing hypertension alongside metabolic disease, this dual-nutrient recommendation is very important.

Nine: If you don’t drink alcohol, don’t start. If you do, limit intake. The 2026 statement takes a harder stance than prior versions by removing any specific safe daily limit and formally recognizing that no amount of alcohol is risk-free for certain cancers, including oral, esophageal, breast, liver, and colorectal cancer. This aligns with the World Health Organization’s standing position and with the 2023 Canadian guidance that eliminated the concept of a safe low-dose threshold entirely.

Where the AHA and the Federal Guidelines Agree

Both the AHA and the 2025–2030 federal guidelines agree on limiting added sugars, limiting saturated fat, limiting ultra-processed foods, limiting alcohol, emphasizing vegetables, fruits, and whole grains, and prioritizing whole food sources over processed ones.

Where They Diverge and Why It Matters

Protein source hierarchy. The AHA places plant proteins first and explicitly advises against red meat. The federal guidelines place animal protein sources first and promotes lean red meat as compatible with healthy dietary patterns. The two positions represent different interpretations of the same evidence base, particularly around cardiovascular outcomes associated with long-term red meat consumption.

Dairy fat. The AHA maintains its longstanding recommendation for low-fat and fat-free dairy. The 2025–2030 federal guidelines recommend full-fat dairy at three servings per day. Here the AHA does something significant: it formally acknowledges that the evidence on full-fat dairy is contested and commits to monitoring that evidence as it evolves.

Hypertension. The federal guidelines make no substantive reference to blood pressure as dietary targets, a notable omission given that hypertension is one of the most significant cardiovascular risk factors and sodium restriction has historically been a central pillar of federal dietary policy. The AHA 2026 statement addresses blood pressure management directly, adds potassium explicitly, and cites the 2025 AHA/ACC blood pressure management guideline recommending avoidance of alcohol for hypertension prevention and treatment.

TMAO: A New Biological Mechanism Linking Red Meat to Cardiovascular Risk

The 2026 AHA statement introduces a specific mechanism linking red meat consumption to cardiovascular harm that operates independently of saturated fat.

When gut bacteria process certain compounds found predominantly in red meat, particularly L-carnitine and choline, one of the byproducts is a metabolite called trimethylamine-N-oxide, or TMAO. Elevated TMAO levels in the bloodstream are associated with atherosclerosis (plaque buildup in arteries), vascular calcification, impaired blood vessel function, and increased platelet activity, all of which raise cardiovascular risk through pathways involving inflammation, oxidative stress, and altered cholesterol metabolism.

Why does this matter beyond the saturated fat argument? Because if TMAO represents a distinct cardiovascular risk pathway from red meat, swapping to lean red meat does not fully address the risk. The associative evidence is consistent, but the causal pathway in humans is not yet fully established. TMAO is a mechanism worth following as the research matures.

The Gut-Heart Axis: Why Fiber Is More Than a Digestive Aid

The 2026 AHA statement gives meaningful attention to the relationship between dietary fiber, the gut microbiome, and cardiovascular health, an area the federal guidelines addressed only superficially.

The gut microbiome functions as a powerful endocrine and immunological organ. Dietary fiber is its primary fuel. When gut bacteria ferment fiber, the byproducts include short-chain fatty acids, particularly butyrate and acetate, that exhibit anti-inflammatory and vasoprotective effects throughout the body. Conversely, a diet low in fiber and high in ultra-processed foods degrades microbial diversity, and that degraded microbiome is associated with systemic inflammation, impaired blood vessel function, and insulin resistance all of which directly increase cardiovascular risk.

These adds a second mechanism through which ultra-processed food consumption causes cardiovascular harm, one that operates through the destruction of the microbial ecosystem that fiber sustains. It also reinforces a broader principle that the AHA itself articulates in its 2026 statement: dietary components do not act in isolation, they act through a complex biological system shaped by the overall quality of the entire dietary pattern.

Four Documents, One Honest Assessment

The Scientific Report of the 2025 Dietary Guidelines Advisory Committee is the most methodologically rigorous of the four and the most plant-forward in its conclusions.

The 2025–2030 Dietary Guidelines for Americans takes the strongest stance against ultra-processed foods and raises protein targets, but is internally contradictory on saturated fat and silent on hypertension.

The 2026 AHA Scientific Statement is the strongest on red meat caution, introduces the TMAO mechanism, adds potassium explicitly, addresses hypertension directly, and acknowledges the full-fat dairy debate for the first time.

The ACC Nutrition and Lifestyle Work Group analysis validates the saturated fat arithmetic contradictions in the federal guidelines and adds cardiovascular outcome data on protein source hierarchy.

No single document is entirely right or wrong. Dietary science is complex and the evidence has real limitations.

A Note on Red Meat: Where the Evidence Lands and Where I Stand

The AHA’s 2026 position on red meat is clear: reduce intake, prioritize plant protein and fish, and treat red meat as a cardiovascular risk factor through both saturated fat content and the TMAO pathway.

The recommendation I stand behind is a balanced intake between animal and plant protein and fat sources as part of a complete whole-food dietary pattern. Practical balance is, in my judgment, more achievable for most people and nutritionally sufficient when the overall dietary pattern is sound.

First, it applies exclusively to whole, unprocessed meat. Industrially processed meat products, deli meats, sausages, hot dogs, fast food patties, carry additional risks from high sodium, preservatives, and chemical additives that are entirely separate from their protein or fat profile. The evidence against processed meat is stronger and more consistent than the evidence against whole red meat, and processed meat should not be treated as a reasonable substitute. Second, the TMAO evidence and the AHA’s harder position on red meat are presented in full so you can make an educated decision on how much to consume. Major cardiology bodies disagree with my position on the specific question of red meat. That disagreement is real and scientifically grounded, even where I assess the overall balance differently.

The purpose of this piece is not to tell you what to conclude. It is to make sure you have the information you need to decide for yourself.

Found this article useful? Share your thoughts. Join the conversation below.

Educational content on The Metabolic Archives is free, because medical information should be accessible to everyone. If you find value in and want to support the work, a paid subscription is available and genuinely appreciated. Visit the About Page for additional information.

Subscribe now

© 2026 The Metabolic Archives. All rights reserved.

In Part 1, we looked at the 2025–2030 Dietary Guidelines and evaluated what they got right and what they got wrong on the specifics: ultra-processed food, protein targets, saturated fat, fiber, protein source hierarchy. The verdict was mixed.

While both the guidelines and their critics are entirely focused on food selection neither addresses how you eat. And the evidence increasingly suggests that the how is as metabolically consequential as the what.

The Nutrient-Counting Trap

The dominant framework in nutrition science and policy for the past half-century has been nutrient arithmetic. Measure the components of food. Set targets for each. Design a diet that hits the targets. It treats food as a collection of independent variables, each exerting its effect separately. The food they come from, the other foods consumed alongside them, the order in which they arrive, the pace at which the meal unfolds, none of these variables appear in the accounting.

Consider two meals with identical nutrient profiles, same protein, same carbohydrate, same fat, same fiber. One is eaten in twenty minutes, starting with bread, followed by meat, with vegetables as a side. The other unfolds over an hour, starting with a vegetable course dressed in olive oil, followed by a protein course, with starch arriving last in modest portions. While the nutrient arithmetic says these meals are equivalent, the metabolic response to them is not.

The Food Matrix, Why the Whole Outweighs the Parts

The metabolic effect of a food is determined by the totality of its composition and structure, what nutritional scientists call the food matrix, not by any single nutrient it contains. A piece of aged cheese is not the same metabolically as an equivalent quantity of processed cheese product, even if the macronutrient profiles look similar on a label.

The clearest everyday illustration of this principle is the difference between an actual potato and instant boxed mashed potatoes. Both are derived from the same plant. Both are labeled as potato on a nutrition panel. The actual potato retains its cellular structure, that structure slows digestion, moderates glucose release, and engages satiety signaling differently than a product in which the cellular architecture has been industrially destroyed and then reconstituted with additives.

Food Sequencing, The Evidence the Guidelines Ignored

A landmark crossover study conducted at Weill Cornell Medicine and published in Diabetes Care in 2015 tested what happened when overweight and obese adults with type 2 diabetes ate the same meal in different orders. When protein and vegetables were consumed before carbohydrates, the postmeal blood glucose area under the curve was 73% lower compared to the carbohydrate-first condition. Postprandial insulin was also significantly reduced.

A subsequent crossover study in adults with pre-diabetes extended the finding: post-prandial glucose peaks were attenuated by about 40% in both the protein-and-vegetables-first and vegetables-first meal compared to carbohydrate-first. The glucose area under the curve was 38.8% lower over 180 minutes when protein and vegetables led the meal.

More recently a 2025 study in Diabetes Care using continuous glucose monitoring in type 2 diabetes demonstrated that carbohydrate-last food order improved time-in-range and reduced glycemic variability. It was not just acutely but over a sustained monitoring period, correlating laboratory findings with real-world conditions.

The sample sizes are modest and the food sequencing literature is still developing. But two things give the findings credibility beyond their sample sizes: the consistency of effect across independent studies in different populations, and the mechanism.

When protein and fat arrive in the gut before carbohydrate, they stimulate the release of glucagon-like peptide-1 (GLP-1) from intestinal cells. GLP-1 slows gastric emptying, suppresses glucagon, and amplifies insulin secretion in anticipation of the carbohydrate load that follows. The result is a more gradual glucose absorption with lower insulin peaks. This is the same physiological pathway that GLP-1 receptor agonist medications exploit pharmacologically. Food sequencing activates it for free through the order in which you choose to eat.

A 16-week behavioral pilot study published in MDPI Nutrients in 2023 found that 94% of participants reported high adherence to carbohydrate-last food order, and 72% reported it was easy to implement. It also naturally improved overall diet quality by increasing protein and vegetable consumption at the start of meals.

Protein Distribution, Not Just How Much, But When

Total daily protein intake is not the only variable that determines whether that protein supports muscle preservation. Adequate protein consumption at each individual meal, particularly breakfast, is equally important. Muscle protein synthesis requires a sufficient leucine threshold to be triggered at each meal. Consuming 100 grams of protein in two large meals while eating little protein at breakfast does not produce the same muscle-preserving effect as distributing that intake more evenly.

A 2015 review in Nutrients by Nowson and O’Connell found that many older adults consume inadequate protein particularly at breakfast, with frail populations falling below the threshold required to stimulate muscle protein synthesis at both breakfast and lunch. The practical implication is direct: if you are targeting 1.2 g/kg daily for muscle preservation, the distribution of that intake across your meals matters and breakfast is where the gap is most likely to be.

Breakfast is considered the most important meal of the day for protein utilization. Studies in both mice and humans (notably a 2025 follow-up on “Chrononutrition”) indicate that the body’s machinery for Muscle Protein Synthesis (MPS) is more sensitive and active in the morning. This results suggest prioritizing protein intake at breakfast time may favor muscle mass preservation and expansion.

What Traditional Meal Cultures Understood Without Knowing Why

I grew up in Spain in the 1960s and 70s when the multi-course meal structure was an ordinary feature of daily life. These large meals were eaten with family and close friends over more than an hour, where social interaction was the dominant aspect.

The sequence was consistent: a light soup and/or a simple salad lightly dressed with olive oil and vinegar, came first. A vegetable or legume course followed. Meat came third. Starch, mostly rice, or potatoes, arrived last. Dessert came in small portions after satiety was already well established.

This meal architecture evolved through centuries of cultural practice, shaped by what worked. The lived experience was simple: by the time the starch course arrived, fullness was sufficient to naturally limit consumption. While dessert portions were small, often could not be finished. The structure of the meal did the work.

This is the beginning of a larger conversation. How different food cultures have instinctively organized eating in ways that solve metabolic problems, a subject we will return to in future articles.

Action Steps: Building Meal Architecture Into Your Daily Life

1. Sequence your meals deliberately. At every meal where sequencing is possible, lead with protein and non-starchy vegetables. Eat your starch last. You do not need to eliminate carbohydrates just change when they arrive.

2. Protect breakfast protein. If you are consuming higher protein intake for muscle preservation, breakfast is the most important meal to target. A breakfast built around quality protein sources activate muscle protein synthesis.

3. Slow the pace of eating. Satiety signaling has a lag, it takes approximately 15–20 minutes for the hormonal signals initiated by eating to reach the brain and register as fullness. A meal eaten in ten minutes bypasses that signaling almost entirely. Slowing down allows the satiety signals to fully establish as intended.

4. Read the ingredient list, not just the label. If the list is long, unfamiliar, and reads like a chemistry catalogue, the matrix has been industrially disrupted. To learn more check my food label article here.

5. Treat eating as a system, not a set of rules. The nutrient-counting framework gives you rules to follow. Understanding why the sequence, the food matrix, and eating pace matters, provides you with an architecture to easily apply on every meal.

Found this article useful? Share your thoughts. Join the conversation below.

Educational content on The Metabolic Archives is free, because medical information should be accessible to everyone. If you find value and want to support the work, a paid subscription is available and genuinely appreciated. Visit the About Page for additional information.

Subscribe now

© 2026 The Metabolic Archives. All rights reserved.

The 2025–2030 Dietary Guidelines for Americans arrived in early 2026 carrying something unusual: a meaningful departure from the process that normally produces them. The Dietary Guidelines Advisory Committee, an independent scientific panel that spends two years reviewing the peer-reviewed literature before each cycle, submitted its report. The federal departments then wrote guidelines that diverged from that report. Several major professional medical organizations, including the American College of Cardiology, weighed in publicly and critically within weeks of publication.

This is an evaluation of the science: an honest accounting of what both documents got right, what they got wrong, and what the gap between them tells you about the current state of nutrition science and policy in the United States.

Why These Guidelines Affect You Even If You Never Read Them

They are the foundational policy document for what is served in every school lunch program in the country, how the military feeds its personnel, how federal nutrition assistance programs are structured, and what public health education campaigns tell Americans about food.

The Advisory Committee report and the final published guidelines are two different documents produced by two different processes. The committee report is the scientific foundation: technically rigorous, academically cautious, and explicit about the strength and limitations of the evidence it reviews. The final guidelines are the policy document.

Where Both Documents Agree

Both documents agree on limiting added sugars, limiting sodium, limiting alcohol, prioritizing vegetables, fruits, and whole grains, and emphasizing whole foods over ultra-processed foods.

What the Guidelines Got Right

Ultra-processed Food An Overdue Reckoning

For the first time in the history of federal dietary guidance, the 2025–2030 guidelines name ultra-processed food directly and unambiguously as something to limit.

The Advisory Committee reviewed the evidence carefully. Its relative caution on this question serve the science better than it serves the people the science is meant to protect. A large nationally representative study with a median eight-year follow-up found that consumption of highly processed foods was associated with higher all-cause mortality even after adjusting for overall diet quality scores suggesting that existing dietary guidelines had not fully captured the harm.

Protein Targets Finally Calibrated to the Right Population

The 2025–2030 guidelines elevate protein recommendations to 1.2–1.6 grams per kilogram of body weight per day, a meaningful upward revision from the longstanding reference daily intake of 0.8 g/kg.

The 0.8 g/kg figure was established from nitrogen balance studies conducted primarily in young adults. It was never designed as an optimal intake target for aging or metabolically compromised populations. For middle-aged and older adults, the population at highest metabolic risk, the evidence consistently supports higher intake. The PROT-AGE Study Group, convened by the European Union Geriatric Medicine Society, recommends 1.0–1.2 g/kg daily for healthy older adults and 1.2–1.5 g/kg for those with acute or chronic illness. The ESPEN Expert Group similarly recommends a minimum of 1.0–1.2 g/kg for healthy older adults, with higher targets for those who are ill or malnourished. A 2025 randomized controlled trial published in Frontiers in Nutrition found that 1.2 g/kg daily was significantly more effective than 0.8 g/kg in preserving muscle mass, improving strength, and reducing abdominal adiposity in elderly women with sarcopenia over twelve weeks.

Sarcopenia, the progressive loss of muscle mass and function with age, is under recognized, under diagnosed, and under treated. It is also one of the most consequential drivers of metabolic deterioration in older adults, also affecting many on GLP-1 treatments targeting obesity.

What the Guidelines Got Wrong

The Saturated Fat Contradiction

The 2025–2030 guidelines retain the evidence-based limit of less than 10% of daily calories from saturated fat, approximately 22 grams on a standard 2,000-calorie diet. In the same document, they recommend three daily servings of full-fat dairy, over-promote red meat consumption, and list butter and beef tallow as acceptable fat sources.

The arithmetic does not work. As Harvard T.H. Chan School of Public Health analysis from January 2026 makes clear, three servings of full-fat dairy alone consume approximately 17 grams of saturated fat leaving roughly 5 grams of daily headroom before a single serving of the red meat as promoted in the document is consumed. This internal incoherence can lead to confusion and potential harm for those strictly adhering to these guidelines.

Eggs, unprocessed meat, and dairy have a place as part of a whole-food dietary pattern. So do plant-based sources of protein and fats such as leafy vegetables, legumes and whole grains. The balance between the two is what makes the saturated fat arithmetic manageable. It is also what the evidence actually supports: not animal protein exclusivity, not plant protein exclusivity, but a whole-food pattern that draws meaningfully from both.

The Fiber Omission

Approximately 94% of Americans fail to meet recommended fiber intake (approximately 25-35 grams daily), according to USDA dietary intake data and the 2025 DGAC Scientific Report. It is the most consistent and consequential nutritional failure in the American diet.

Fiber drives satiety through intestinal bulk. It slows glucose absorption and blunts the postprandial insulin spike that follows a carbohydrate load. It supports gut microbiome diversity in ways that are increasingly linked to metabolic and cardiovascular health. It reduces cardiovascular risk through multiple independent mechanisms. The guidelines’ relative silence on fiber is the most significant missed public health opportunity in the document.

The Protein Source Hierarchy

The guidelines list animal protein sources first within the protein food group, with plant sources positioned as secondary alternatives. The Advisory Committee’s recommendation moved in the opposite direction, toward plant-forward protein patterns, based on cardiovascular outcome data. As the American College of Cardiology’s Nutrition and Lifestyle Work Group noted in January 2026, this hierarchy, animal sources first, conflicts with the evidence on cardiovascular outcomes.

The relevant scientific axis here is not animal versus plant, it is whole food versus industrially processed food. Both animal and plant protein and fats in whole foods belong in a balanced dietary pattern. The guidelines’ implicit animal over plant source hierarchy sends a message science and cardiovascular evidence actively contradicts.

The Deeper Problem And What Comes Next

The failures described above are real. But they are also failures within a shared framework. That framework is nutrient arithmetic, the idea that what matters most about a diet is the accounting of its component parts: saturated fat grams, protein targets, fiber thresholds, added sugar percentages.

That framework captures something but misses something more important: food is a system, and the metabolic effect of what you eat is determined by the integrity of the whole not the sum of its nutrients.

A diet system is not only comprised to the nutrients it contains. The matrix, sequence, and pace matters as much. None of that appears in the 2025–2030 guidelines, or in the DGAC report, or in the critical response to either.

That is the subject of Part 2.

Action Steps: What to Take From This

1. Make ultra-processed food the primary target. Not just fat, carbohydrates or protein. The single most consequential dietary shift most Americans can make today is reducing ultra-processed food consumption.

2. Audit your protein intake, especially at breakfast. If you are over 50, the updated protein targets are appropriate for you. Aim for 1.2 g/kg of your body weight daily, distributed across meals. A 70 kg adult needs roughly 85 grams per day and the research suggests that many older adults fall short specifically at breakfast, the meal that matters most for muscle protein synthesis over the course of the day.

3. Balance animal and plant protein sources. Not because animal foods are harmful, but because the balance is what makes both the saturated fat arithmetic and the cardiovascular evidence work in your favor.

4. Prioritize fiber deliberately. Aim for at least 25–35 grams of fiber daily from whole food sources: vegetables, legumes, whole grains, fruit. This is where the guidelines failed, redress this failure on your own.

5. Read labels for what they don’t tell you. A food with a favorable nutrient profile on the label can still be ultra-processed. The ingredient list tells you more about a food’s metabolic impact than any single nutrient figure.

6. Limit sodium while increasing potassium intake. Limiting sodium is a good recommendation, but studies increasingly point to the beneficial effects of potassium on blood pressure control. Keep in mind over 70% of dietary sodium in the American diet comes from packaged and prepared foods, not from table salt added during cooking or eating. Yet another reason to limit ultra-processed food consumption.

Found this article useful? Share your thoughts. Join the conversation below.

Educational content on The Metabolic Archives is free, because medical information should be accessible to everyone. If you find value and want to support the work, a paid subscription is available and genuinely appreciated. Visit the About Page for additional information.

Subscribe now

© 2026 The Metabolic Archives. All rights reserved.